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1. Summary 
Glioblastoma is a highly destructive primary brain cancer with poor prognosis despite 
aggressive treatment consisting of surgical resection, radiation, and chemotherapy. 
Hence, development of novel treatment strategies represents a continuous need. One 
treatment approach aims to revert the suppressive tumor microenvironment into a pro-
inflammatory microenvironment leading to tumor rejection. Multiple clinical trials are 
currently ongoing using intratumoral delivery of the pro-inflammatory cytokine 
interleukin (IL)-12 with the aim of minimizing toxicity while maximizing efficacy. 
However, improvement of IL-12 based immunotherapy requires an immunological 
understanding of the mechanistic underpinnings. Using a syngeneic mouse model for 
glioblastoma, we previously showed that intratumoral delivery of IL-12 leads to tumor 
rejection. Here we show that tumor control is dependent on IL-12 signaling in tumor-
invading (cluster of differentiation 8) CD8+ T cells, driving local expansion. We observed 
a concomitant influx of myeloid cells into the tumor microenvironment. However, 
chemokine-receptor 2 (CCR2)-dependent monocyte-derived cells were dispensable for 
IL-12-mediated tumor rejection. Tumor control was supported by CD103+ dendritic cells 
(DCs) found within the tumor microenvironment. However, in the absence of CD103+ 
DCs mice seem to control, but are not able to reject IL-12 expressing tumors. 
 
Our findings provide new insights into the mechanism of IL-12 mediated glioma 
rejection, including requirement of directly and indirectly responsive cell types, to 
consider for the development of novel treatment strategies. 
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2. Zusammenfassung 
Das Glioblastom ist ein bösartiger Hirntumor, der trotz aggressiver Behandlung 
bestehend aus chirurgischer Resektion, Strahlentherapie und Chemotherapie schlechte 
Prognosen aufzeigt. Daher ist es essenziell kontinuierlich neue Behandlungsstrategien zu 
entwickeln. Ein Behandlungsansatz zielt darauf ab die suppressive 
Tumormikroumgebung in eine proinflammatorische Mikroumgebung umzuwandeln, die 
zur Abstossung des Tumors führt. Aktuelle klinische Studien basieren auf der 
intratumoralen Verabreichung des pro-inflammatorischen Zytokin Interleukin (IL) -12. 
Das Ziel ist, die Toxizität zu minimieren und gleichzeitig die therapeutische Wirksamkeit 
zu maximieren. Voraussetzung für die Entwicklung der IL-12-basierten Immuntherapie 
ist das Verständnis der grundlegenden immunologischen Mechanismen. Mit einem 
Mausmodell für das Glioblastom konnten wir nachweisen, dass die intratumorale 
Verabreichung von IL-12 zur Tumorabstossung führt. 
In der vorliegenden Studie zeigen wir, dass die IL-12 induzierte Tumorkontrolle von der 
Wirkung auf tumor-infiltrierende CD8+ T-Zellen basiert und zu deren Expansion führt. 
Gleichzeitig war eine Anhäufung von myeloiden Zellen in der Tumormikroumgebung zu 
beobachten, wobei CCR2-abbhängige monozytische Zellen für die IL-12 vermittelte 
Tumorabstossung entbehrlich waren. Die Tumorkontrolle wird von CD103+ 
dendritischen Zellen innerhalb der Tumormikroumgebung unterstützt, wobei in 
Abwesenheit von CD103+ dendritischen Zellen eine Tumorkontrolle, aber keine 
Abstossung von IL-12 überexprimierenden Tumoren stattfindet. 
 
Unsere Ergebnisse liefern neue Erkenntnisse über den Mechanismus der IL-12-
vermittelten Gliomabstossung, einschliesslich der direkt und indirekt involvierten 
Zelltypen, die für die Entwicklung neuer Therapiestrategien Berücksichtigtung finden  
sollten. 
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3. Abbreviations 
APC Antigen presenting cell i.v. intravenous 
ATP adenosine 5´-triphosphate IPP Isopentenyl 
pyrophosphate αGalCer α-galactosylceramide KIR Killer-cell 
immunoglobulin- Batf3  Basic Leucine Zipper Factor   like receptors 
 ATF-Like Transcription 3 IRF8 Interferon regulatory 
BBB Blood brain barrier  Factor 8 
BLI Bioluminescence imaging LN Lymph node 
BM Bone marrow MHC Major histocompatibility 
BSA Bovine serum albumin  complex 
CAR Chimeric antigen receptor moDC Monocyte-derived 
dendritic cell CCL2 Chemokine (C-C) motif ligand 2 MAP Mitogen-activated protein 
CCR2 Chemokine (C-C) motif receptor 2 MCA 3-methylcholanthrene 
cDC Classical dendritic cell MDSC Myeloid-derived 
suppressor CNS Central nervous system  cell 
cLN Cervical lymph node MICA MHC class I polypeptide- 
CD Cluster of differentiation  related sequence A 
CT Computed Tomography MIP-1α Macrophage 
inflammatory CTL Cytotoxic T cell  proteins 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 MRI Magnetic resonance 
DAMPs Damage-associated molecular 
patterns 
 imaging 
DC Dendritic cell NKG2D Natural-killer group 2, 
EBI3 Epstein-Barr Virus Induced 3  member D 
EGFR Epidermal growth factor receptor  NK cell Natural killer cell 
ELISA Enzyme-linked immunosorbent NKT cell Natural killer T cell 
 Assay PAMPs Pathogen-associated 
FCS Fetal calf serum  molecular patterns 
Flt3l FMS-like tyrosine kinase 3 ligand PBS Phosphate buffered saline 
FoxP3 Forkhead box P3 PD-1 Programmed cell death 
protein 1 FTY720 Fingolimod pDC Plasmacytoid dendritic 
cell GFAP Glial fibrillary acidic protein PD-L1 Programmed death ligand 
1 GL-261 Glioma-261 PET Positron-emission 
GM-CSF Granulocyte/macrophage colony  tomography 
 stimulating factor rAAV Recombinant adeno- 
gp100 Glycoprotein 100  associated virus 
HMGB1 High mobility group box 1 protein Rag recombination-activating 
HSV Herpes simplex virus  gene 
i.c. Intracranial RAE-1 Retinoic acid early  
IDH Isocitrate dehydrogenase  inducible 1 
IDO Indoleamine 2,3-dioxygenase RB Retinoblastoma-
associated IgG Immunoglobulin G ROI Region of interest 
IL Interleukin RT Room temperature 
ILC Innate lymphoid cell SIRPα Signal regulatory protein 
α IFN Interferon s.c. subcutaneous 
IP-10 Interferon gamma-induced protein 
10 
SFV Semliki Forest virus 
STAT Signal transducer and activator of   
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 transcription   
TAM Tumor-associated macrophage   
TCR T cell receptor   
TGF-β Transforming growth   
 factor-β   
Th T helper cell   
TIL Tumor-infiltrating lymphocyte   
TMZ Temozolomide   
TNF Tumor necrosis factor   
TP53 Tumor suppressor 53   
Tregs Regulatory T cells   
TRP2 Tyrosinase-related protein 2   
VEGF Vascular endothelial growth factor   
VSV vesicular stomatitis virus   
WT Wild type   
Zbtb46 Zinc finger and BTB domain    
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5. Introduction 
5.1. Overview of cancer 
To date, cancer remains the second leading cause of death worldwide, responsible for 8.8 
million deaths in 2015. Arising from a single abnormal cell dividing without control, the 
primary risk factor for developing cancer is increasing age (86% of cancers diagnosed in 
the U.S. affect people older than 50 years). However, external factors, such as tobacco or 
physical inactivity and internal factors, such as genetic predisposition or immune 
conditions, can increase the risk of cancer. Based on the overall experience in the general 
population, the lifetime risk of developing cancer has been estimated to be 42% in men 
and 38% in women in the U.S. [1]. 
In the past decades, overall patient survival has significantly improved across cancer 
types. In this respect, the 5-year relative survival rate combining all cancers increased 
from 49% during 1975-1977 to 69% during 2005-2011 [1]. Improved survival rates are 
mainly due to advances in technology, leading to early detection and prevention [2]. 
Moreover, advances in understanding the genetics of cancer development, the possibility 
of expression profiling of cancer cells and increased understanding regarding the 
involvement of the immune system during cancer progression, have paved the way for 
targeted therapies and immunotherapies in addition to surgery, radiation, and 
chemotherapy [2]. However, many cancers, among them highly malignant tumors of the 
CNS remain incurable despite aggressive therapy. 
 
5.1.1. The hallmarks of cancer 
Cancer development seen from the evolutionary perspective comprises the stepwise 
acquisition of biological capabilities. The transition from a normal to a neoplastic cell is 
believed to require traits including sustained proliferative signaling, replicative 
immortality, resisting cell death, inducing angiogenesis, evasion of growth suppressors 
and activation of invasion and metastasis  [3]. Summarized in the hallmarks of cancer, 
the acquisition of these six traits were recently supplemented by the hallmarks of 
reprogramming of energy metabolism and evasion of immune destruction, as well as the 
enabling characteristics of genome instability and tumor-promoting inflammation  
(Figure 1) [4].  
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Figure 1: The hallmarks of cancer. Initially described as the six hallmarks, consisting of sustained 
proliferative signaling, replicative immortality, evasion of growth suppressors, resisting cell death, inducing 
angiogenesis and activation of invasion and metastasis in 2000 by Hanahan and Weinberg [3]. Emerging 
concepts were added in 2011 and included genome instability and mutation, tumor-promoting 
inflammation, reprogramming energy metabolism and evading immune destruction [4]. Adapted from [4]. 
 
5.1.1.1. Sustaining proliferative signaling 
Sustained proliferative signaling represents the most prominent acquired trait of cancer 
cells. While healthy tissues possess multiple regulatory mechanisms to control cell 
numbers, cancer cells exploit numerous ways to ensure abnormal proliferation. For 
example, defects in negative-feedback mechanisms account for the uncontrolled 
proliferation of cancer cells. Moreover, cancer cells may regulate their growth by 
releasing growth factor ligands and simultaneously expressing the cognate receptor, thus 
inducing autocrine proliferation [4, 5]. Overexpression of the receptor itself may enable 
cancer cells to become hyper-responsive to growth factors [6]. Alternatively, cancer cells 
may stimulate the production of growth factors by surrounding healthy tissue [4, 7, 8].  
The most studied regulators of the proliferative signaling circuitry are the GTPases H-
Ras, K-Ras, and N-Ras, with K-Ras mutations being most abundant in several types of 
cancer [9]. Constitutive activation due to mutations at codons 12, 13 or 61 has multiple 
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effects such as activation of Raf kinases leading to activation of the mitogen-activated 
protein (MAP)-kinase pathway resulting in increased proliferation. Additionally, 
activation of the MAP-kinase pathway can be a result of somatic mutations in the BRAF 
gene itself. Notably, constitutive activation of the serine/threonine kinase BRAF (V600E) 
is found in 50% of epithelioid glioblastomas and 66% of malignant melanomas (V600E) 
[10-13]. 
 
5.1.1.2. Evading growth suppressors 
Apart from ensuring sustained proliferative signaling, cancer cells also need to acquire 
the capacity to evade growth suppressors. Evasion frequently involves the tumor 
suppressor retinoblastoma-associated (RB) and TP53 proteins. While RB is responsible 
for the decision of cell cycle progression (or cell cycle arrest) influenced primarily by 
extracellular-derived inhibitory signals, TP53 mainly acts upon intracellular signals, e.g., 
related to stress. However, apart from decisions on cell cycle progression or arrest (e.g., 
due to extensive genome damage), TP53 may also lead the cell into programmed cell 
death in case of irreparable damage (further described in 5.1.1.3) [4]. Notably, TP53 
mutations leading to loss-of-function represents an early and frequent genetic alteration 
occurring in 60% of low-grade astrocytomas [14]. An additional mechanism leading to 
evasion of growth suppressors results from mutations in genes such as NF2. In healthy 
cells, NF2 is part of the contact inhibition mechanism leading to cell cycle arrest when 
cells reach a high density. In cancer cells, loss-of-function of NF2, and thereby loss of 
contact inhibition, leads to uncontrolled growth [4]. 
 
5.1.1.3. Resisting cell death 
Programmed cell death (apoptosis) defines the orderly and efficient removal of damaged 
cells  [4, 15]. Triggered by extracellular factors (such as Fas ligand/Fas receptor 
interaction) or intracellular signals (e.g., genotoxic stress), the apoptotic machinery 
requires a controlled counterbalance of proteins responsible for the inhibition (e.g., Bcl-
2) or induction (such as Bax and Bak) of apoptosis  [4, 16]. Deregulation of apoptosis, 
and thereby resistance of cancer cells to cell death has been established as a hallmark of 
cancer, responsible for tumor development, progression and resistance to therapy [15]. In 
this respect, mutations of Bcl-2 have been identified to confer resistance of melanoma 
cells to the chemotherapeutic paclitaxel [17]. 
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5.1.1.4. Enabling replicative immortality 
Healthy cells may only run through a limited number of growth-and-division cycles 
before entering a constant non-proliferative state (senescence) or a crisis phase leading to 
cell death [4]. Responsible for the limited proliferation capacity are telomeres, a region 
of repetitive nucleotide sequences that protect the end of chromosomes. Every division 
shortens telomere length until telomeres cannot protect chromosome ends anymore, 
leading the cell to senescence or crisis. Cancer cells circumvent this limited proliferative 
capacity by expressing significant levels of the enzyme telomerase, which adds telomere 
repeats, preventing senescence or crisis [3, 4]. Notably, mutations in the promoter of the 
telomerase reverse transcriptase gene leading to increased expression of telomerase 
account for a frequent event in many tumor types, e.g., found in 83% of glioblastoma 
samples [18, 19]. 
 
5.1.1.5. Inducing angiogenesis 
Normal tissues and tumors require a constant supply of nutrients and oxygen for their 
growth and survival. In healthy tissues, the development of vasculature is a tightly 
regulated process, occurring during embryogenesis and only transiently in adults, e.g., 
during wound healing. The formation of vasculature encompasses the steps of new 
endothelial cells arising, assembly of endothelial cells into tubes (vasculogenesis) and the 
growth of new vessels from existing ones (angiogenesis). To sustain the supply of 
nutrients and oxygen for neoplastic growth, tumors frequently activate the “angiogenic 
switch” driving the formation of new vessels [3, 4]. One of the most prominent angiogenic 
regulators is the vascular endothelial growth factor-A (VEGF-A). In this regard, 
angiogenesis in human glioma involves a paracrine mechanism of VEGF produced by 
glioma cells and flt-1, a tyrosine-kinase receptor for VEGF expressed in endothelial cells 
[20]. Inhibitors targeting VEGF signaling (Bevacizumab) are approved by the FDA as a 
treatment for glioblastoma in some countries. However, development of resistance to such 
therapy suggests that tumors can adapt to bypass antiangiogenic signals [21]. 
 
5.1.1.6. Activating invasion and metastasis 
Metastasis, the formation of secondary tumors in distinct organs, is tightly connected to 
mortality and morbidity in cancer patients [22]. While two decades ago, the underlying 
mechanisms were mostly unclear, we now know that invasion and metastasis occurs in a 
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sequential cascade. Beginning with the invasion of cancer cells into the surrounding 
tissues, cancer cells intravasate into the blood and lymphatic vessels. Then, cancer cells 
transit through the lymphatic and hematogenous system, before extravasating into the 
parenchyma of distant tissues forming micrometastasis and eventually macroscopic 
tumors [4]. One of the best-characterized alterations found in transformed cells associated 
with invasion and metastasis describes the cell-to-cell adhesion molecule E-cadherin, 
responsible for binding cells within tissues. In this regard, downregulation or mutational 
inactivation of E-cadherin is found in multiple aggressive human carcinomas [4, 23].  
Regarding the invasion and metastasis into the CNS, secondary tumors are found in ~15% 
of cancer patients. Among solid tumors, lung and breast cancers are the most common to 
metastasize to the CNS [24]. 
 
5.1.1.7. Deregulating cellular energetics 
In addition to providing sufficient nutrients and oxygen through increased angiogenesis 
(section 5.1.1.5), neoplastic cells are required to adjust their energy metabolism to ensure 
cell growth and division. Under normal conditions, cells metabolize glucose via 
glycolysis to pyruvate and subsequently to carbon dioxide in the process of oxidative 
phosphorylation. Depending on the availability of oxygen, this reaction yields high 
amounts of adenosine 5´-triphosphate (ATP), the cell’s energy source. In cancer cells, 
however, a metabolic switch occurs even in the presence of oxygen. By reprogramming 
their metabolism, cancer cells reach a state of aerobic glycolysis, also referred to as the 
Warburg effect [25]. In this respect, cancer cells upregulate glycolysis and lactic acid 
fermentation instead of normal aerobic respiration, ultimately yielding lower amounts of 
ATP. To compensate lower ATP levels, cancer cells frequently upregulate glucose 
transporters leading to increased amounts of glucose in the cytoplasm. This knowledge 
has led to the development of widely used diagnostic tools like positron emission 
tomography (PET) with a radiolabeled glucose analog to detect increased uptake and 
metabolism of glucose in many human tumors [4]. Notably, upregulation of the glucose 
transporter GLUT3 has been correlated with poor survival in brain tumors [26]. One 
explanation for this metabolic switch is the frequently occurring hypoxia in solid tumors. 
Alternatively, increased availability of products related to glycolysis might support the 
synthesis of macromolecules and organelles necessary for assembling new cells [4].  
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5.1.1.8. Genome instability and mutation 
The successful development of neoplastic cells relies on either mutational or epigenetic 
change affecting the regulation of gene expression. In addition to loss-of-function of 
tumor suppressors like TP53 (described in section 5.1.1.2), frequent inactivating 
mutations or epigenetic repressions occur in the genome maintenance systems, the so-
called “caretakers” of the genome [4]. Defects in caretaker genes can, for instance, 
influence the capability of detecting DNA damage and prevent the repair of damaged 
DNA [4, 27]. Conversely, introducing mutant copies of caretaker genes into mouse 
germline has been shown to increase cancer incidence [4, 28], underlining the importance 
of genome instability as enabling characteristic of carcinogenesis. 
 
5.1.1.9. Tumor-promoting inflammation 
Neoplastic lesions can contain varying numbers of immune cells ranging from subtle 
infiltration to gross inflammation. While the infiltration of immune cells was interpreted 
as an attempt of the immune system to attack a neoplastic lesion, it is now believed that 
tumor-associated inflammation can also enhance tumorigenesis and progression. In this 
respect, inflammation can support the hallmarks described above in multiple ways, such 
as through the supply of growth factors supporting sustained proliferative signaling or by 
providing survival factors preventing cell death [4]. A detailed description of tumor-
promoting inflammation will follow in section 5.2.1.3. 
 
5.1.1.10. Evading immune destruction 
Given the attempts of the immune system to eradicate tumors, tumors are believed to be 
under constant immune selection pressure to evade detection. How components of the 
immune system are disabled, preventing tumor eradication, will be described in detail in 
section 5.2.1.3. 
 
In summary, the hallmarks of cancer describe the acquisition of biological capabilities 
that lead to the development of a clinically apparent malignancy. Given the complexity 
of tumor-host immunological interactions, the involvement of the immune system during 
cancer progression will be described in the following sections. 
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5.2. The immune system and cancer 
5.2.1. From cancer immunosurveillance to immunoediting 
Already in the early 1900s, it has been suggested by Paul Ehrlich that the immune system 
plays a crucial role in controlling cancer, by postulating that cancer would be frequent in 
long-lived organisms without protective immunity [29]. However, since function and 
components of the immune system remained mostly elusive, it was not possible to verify 
this hypothesis. Improved understanding of the components of the immune system and 
availability of inbred mouse strains led MacFarlane Burnet and Lewis Thomas to the 
theory of “cancer immunosurveillance,” postulating that adaptive immunity is preventing 
cancer development [30, 31]. Crucial for the tenet of tumor immunology was the 
discovery of tumor antigens, proven by injecting mice with chemically induced tumors.  
In these experiments, subsequent re-challenge with the same tumor led to tumor 
protection, thus proving the existence of tumor antigens [32, 33]. Nevertheless, the 
concept of cancer immunosurveillance received great skepticism, arguing that cancer 
susceptibility of spontaneous and carcinogen-induced tumors was similar in 
immunocompetent and immunodeficient mice [33-35]. Moreover, it was reasoned that 
tumor cells do not possess the required danger signals to activate the immune system [36]. 
Others argued that tumor cells were resembling healthy cells to the extent that tumor cells 
could not be recognized as foreign [37]. Additionally, the observation of persistent 
activation of innate immunity promoting cellular transformation and tumor outgrowth 
was explained by precluding a protective function of the immune system [33, 38, 39].  
In the 1990s, however, the concept of cancer immunosurveillance was reconsidered. Due 
to advances in transgenic mouse technology resulting in the availability of mouse models 
for distinct immunodeficiencies on pure genetic backgrounds and the use of monoclonal 
antibodies, cytokines, and cell types were now associated with a protective role of the 
immune system against tumor formation. It was shown that mice lacking adaptive 
immunity and mice deficient in the pro-inflammatory cytokine interferon (IFN)-γ were 
more susceptible to carcinogen-induced and spontaneous tumors [33, 40, 41].  
In 2001, the role of the immune system in cancer was reassessed once again, based on the 
discovery that the immune system is capable of suppressing cancer growth and selecting 
tumor cells more fit to survive [33, 41]. In the underlying experiments, both 
immunocompetent and immunodeficient mice were subjected to a primary carcinogen-
induced tumor challenge. Tumor cell lines were established from both groups and 
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subsequently injected into naïve WT recipients. Monitoring of the growth profile led to 
the finding that tumor cells derived from immunodeficient mice were rejected by naïve 
WT recipients, while mice receiving tumor cells initially derived from immunocompetent 
mice were not able to reject the tumor. It was concluded that tumor cells from mice with 
a compromised immune system had more immunogenic, “unedited” profile, compared to 
mice with an intact immune system bearing “edited” tumors. These experiments provided 
the foundation of the cancer immunoediting hypothesis, consisting of the 3 phased 
“elimination, “equilibrium” and “escape,” shown in Figure 2 [33, 41, 42]. 
 
Figure 2: The concept of cancer immunoediting. Carcinogen or radiation-induced challenge can lead to 
the development of transformed cells given that mechanisms of intrinsic tumor suppression fail. These 
highly immunogenic transformed cells can release danger signals, express tumor-specific antigens and 
ligands activating the innate arm of immunity. Within this so-called elimination phase of cancer 
immunoediting, both innate and adaptive immunity participate in extrinsic tumor suppression mechanisms, 
e.g., through the release of perforin into the target cell inducing its apoptosis. Rare variants not eliminated 
can enter the equilibrium phase. During this phase, tumor outgrowth is prevented by the adaptive arm of 
immunity. Notably, editing of tumor immunogenicity merely occurs in the equilibrium phase. Concomitant 
immune selection pressure and genetic instability of tumor cells allow rare variants to enter the escape 
phase, in which the tumor uses an intrinsic mechanism like antigen loss, but also tumor-promoting 
inflammation recruiting immuno-suppressive cells to form a clinical malignancy. Adapted from [33]. 
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5.2.1.1. Elimination 
Elimination represents the first phase of cancer immunoediting. Given that intrinsic tumor 
suppression mechanisms fail to maintain normal somatic tissue, this phase is 
characterized by localizing, recognizing and destroying transformed cells to prevent the 
development of malignancy. Even though the underlying mechanisms of how early tumor 
development is being prevented are not fully understood, many of the molecules 
participating in the elimination phase have been discovered. These discoveries derived 
for instance from mouse models lacking immune cell subsets, recognition molecules, 
effector pathways or cytokines, which were compared to wild-type mice in regards to 
tumor initiation, growth, and metastases [33, 43]. Apart from the dependency of 
elimination on tumor characteristics such as anatomic location and growth rate, these 
experiments showed that the elimination phase involves both, innate and adaptive 
immunity. In this respect, localization of transformed cells has been associated with 
classical danger signals such as Type 1 IFNs, found early during tumor development. 
Type 1 IFNs activate dendritic cells (DCs) and thus induce adaptive anti-tumor immune 
responses [36]. Also, damage-associated molecular pattern molecules (DAMPs) released 
by dying tumor cells, e.g., the high mobility group box 1(HMGB1) have been associated 
with the elimination phase. DAMPs alert the immune system to the presence of dying 
tumors cells, triggering immunogenic cell death [44]. 
Importantly, the elimination phase is characterized by the infiltration of multiple immune 
cell subsets. Triggered by tissue disruption of invasively growing tumor cells, 
inflammatory signals released recruit cells of the innate immune system to the tumor site. 
Natural killer (NK) cells, NKT cells, gamma-delta (γδ) T cells, macrophages and 
dendritic cells (DCs) are among these first infiltrates, subsequently recruiting cells of 
adaptive immunity recognizing specific targets and eliminating transformed cells. The 
main characteristics of these infiltrating cells, as well as their contribution to extrinsic 
tumor suppression, will be described below.  
 
Natural killer cells 
NK cells are lymphocytes belonging to the innate immune system. Involved in surveying 
the body for stressed and abnormal cells, NK cells integrate signals from various 
activating and inhibitory receptors. Primary activating receptors include for instance 
NKG2D, binding to stress ligands such as retinoid acid early-inducible protein (RAE)-1 
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(mouse) and MHC-class-I-polypeptide-related sequence A (MICA, human), frequently 
expressed on tumor cells due to constitutive activation of DNA-damage response 
pathways [45]. Activating receptor signaling in NK cells can induce apoptosis in target 
cells through the release of the lytic granules containing perforin and granzymes. Perforin 
release induces apoptosis by creating pores in the plasma membrane, while granzymes 
enter the target cells triggering apoptotic pathways by cleaving precursors of caspases. 
Another NK cell-related effector mechanism is the secretion of various cytokines and 
chemokines such as IFN-γ, granulocyte-macrophage colony stimulating factor (GM-
CSF) and macrophage inflammatory protein (MIP)-1α [46]. Inhibitory receptors such as 
members of the Killer Cell Immunoglobulin-like-Receptors (KIR) family (human) and 
the C-type lectin-like Ly49 (mouse) bind to Major Histocompatibility Complex class I 
molecules (MHCI) expressed on healthy cells, preventing NK cell activation. However, 
both transformed and virally infected cells frequently display reduced or altered 
expression of MHCI, leading to the reduced presentation of self-peptides. NK cells detect 
changes in self-molecules, attacking virus-infected and transformed cells with impaired 
MHCI expression, as described in the “missing-self hypothesis” [47].  
In preclinical models, antibody-mediated depletion of NK cells has been shown to result 
in the increased susceptibility to MCS-induced sarcomas. Whereas RAE-1 transgenic 
mice, characterized by the defective killing of the NKG2D pathway, display increased 
DMBA/TPA (7,12-di-methylbenza-anthracene/12-O-tetradecanoyl-phorbol-13-acetate) -
induced skin tumors [48]. 
 
Natural killer T cells 
NKT cells share both features of NK and T cells and are thus grouped into the family of 
innate-like lymphocytes. NKT cells express both NK1.1, a classical NK cell marker 
(murine C57BL/6) and the αβ T cell receptor (TCR). Expressing the semi-invariant TCRα 
chain (Vα14-Jα18 TCR in mice, Vα24-Jα18 in humans) together with the Vβ chains 
(Vβ8,7 and 2 in mice; Vβ11 in humans), NKT cells preferentially recognize glycolipids 
presented by the non-classical MHC-like molecule CD1d, such as α-galactosylceramide 
(α-GalCer) [49]. NKT cells activate cytotoxic functions like NK cells in a perforin-
dependent fashion. Additionally, NKT cells produce various cytokines, such as IFN-γ, 
TNF, Interleukins (IL)-2, -4, -10, -13, -17, -21, -22 and GM-CSF, thus secreting both 
Th1/pro-inflammatory and Th2/anti-inflammatory cytokines [49]. Moreover, NKT cells 
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can induce DC maturation, enhancing priming and CD8+ T cell responses. In tumor 
immunity, type I NKT subsets promote tumor control, in contrast, to type II NKT cells 
which can suppress anti-tumor immune responses. Moreover, mice lacking invariant 
NKT cells (Jα18-/- mice) have an increased susceptibility to 3´-methylcholanthrene 
(MCA)-induced sarcomas compared to wild-type mice [50], underlining the role of 
invariant NKT cells during the elimination phase in some murine cancer models.  
 
Gamma delta T cells 
Gamma delta (γδ) T cells belong to the family of non-conventional or innate lymphocytes. 
Unlike conventional αβ T cells, γδ T cells do not express CD4 and CD8 lineage markers 
and rearrange the γ and the δ-chain segments of the TCR gene locus. However, like other 
T cell populations, activation and acquisition of effector functions depend on TCR 
engagement. Recognizing a variety of self and non-self-antigens, such as small peptides 
and phospholipids, γδ T cells recognize molecules frequently increased in tumors. For 
instance, metabolites of the isoprenoid pathway, such as isopentenyl pyrophosphate (IPP) 
can be sensed as a danger signal by γδ T cells [51]. Like NK cells, γδ T cells can also 
recognize stress ligands, such as RAE-1, through binding to the activating receptor 
NKG2D. Additionally, γδ T cells can kill infected, activated or transformed cells by 
triggering death-inducing receptors, such as Fas and TRAIL, and through the release of 
the cytotoxic molecules perforin and granzyme [52]. Lack of γδ T cells (Tcrd-/-) has been 
associated with increased susceptibility to MCA-induced sarcomas and DMBA/TPA-
induced skin tumors [53]. 
 
Macrophages 
Macrophages are a crucial component of the innate immune system and prominent cells 
within tumors. Providing an immediate defense against pathogens, macrophages engulf 
and digest cellular debris, microbes, and cancerous cells. Macrophages recognize 
pathogen-associated molecular patterns (PAMPs) and detect endogenous danger signals 
present in necrotic tumor cells. In the tumor microenvironment, cellular composition and 
disease stage dictate whether macrophages adopt a tumor-suppressing (M1) or tumor-
promoting phenotype (M2). M1  macrophages require IFN-γ for their development and 
secrete multiple pro-inflammatory cytokines, such as IL-12, IL-1β, and TNF-α, thus 
supporting the generation of a Th1 immune response [54]. Moreover, M1 macrophages 
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contribute to tumoricidal activity by producing reactive oxygen species [55]. In contrast, 
in the escape phase of cancer immunoediting, macrophages are biased towards an M2-
polarized phenotype, promoting tumor growth and metastasis (described in section 
5.2.1.3). 
Despite not being related to the elimination phase of cancer immunoediting, therapeutic 
use of macrophages has been suggested in the context of blocking the CD47 molecule on 
tumor cells. Expression of CD47 functions as a “don`t eat me” signal upon interaction 
with the signal regulatory protein (SIRP)α inhibitory receptor on macrophages and 
blockade of CD47 can lead to a macrophage-dependent elimination of tumor cells [56, 
57].  
 
Dendritic cells 
Dendritic cells are a subset of innate cells required for the initiation of T cell responses. 
Thus, DCs have a pivotal role in pathogen uptake and antigen presentation, linking innate 
and adaptive immune responses, presenting immunogenic epitopes in the context of 
MHCI and MHCII. As depicted in Figure 3, DCs are a group of heterogeneous cells, 
under steady-state conditions divided into lymphoid tissue-resident DCs and migratory 
DCs, and blood-derived DCs in inflammatory settings. For simplification purpose, this 
thesis will refer to the major subsets of migratory, resident DCs and monocyte-derived 
DCs (moDCs). 
 
Figure 3: Main subsets of mouse DCs. Organization of DCs in lymph node and spleen under steady-state 
conditions and subsets associated with inflammation (adapted from [58]).  
 
Migratory DCs sample antigens from peripheral tissues, migrating to draining lymph 
nodes via afferent lymphatics to induce T cell priming. Resident DCs are found in lymph 
nodes, spleen, and thymus. Depending on the subtype, resident DCs differ in the capacity 
to present antigens in the context of MHCI or MHCII. 
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MoDCs arise under inflammatory conditions and are blood-derived. Differentiating from 
monocytes in response to GM-CSF or Toll-like receptor 4 ligands, moDCs rapidly acquire 
prototypical features of DCs. Moreover, moDCs possess potent antigen-presenting 
capacity in the context of both MHCI and MHCII [58]. 
In the context of the elimination phase, DCs primarily function to induce an adaptive anti-
tumor immune response. Responding to danger signals and cellular stress in the tumor 
microenvironment, DCs transport tumor antigens to draining lymph nodes for T cell 
activation. Moreover, it has been shown that tumor rejection can require migratory and 
resident DCs to sense type I IFNs for the initiation of early tumor responses and to 
enhance cross-presentation of tumor antigens to CD8+ T cells [59, 60].  
 
Conventional T cells 
T cells are crucial players in the adaptive, cellular immune response. Originating from 
hematopoietic stem cells in the bone marrow, conventional T cells migrate and mature in 
the thymus, where they somatically rearrange gene segments of the α- and the β-chain 
forming the TCR. Rearrangement requires enzymes encoded by the recombination-
activating genes (Rags). There are two Rag gene products, RAG-1 and RAG-2, which are 
exclusively expressed in lymphocytes. Thus, Rag1-/- and Rag2-/- mice are devoid of all 
lymphocytes, including T cells, NKT cells and γδ T cells and also B cells, representing 
the humoral part of the adaptive immune response [61, 62]. Accordingly, Rag1-/- and 
Rag2-/- have been shown to have increased susceptibility to multiple induced tumors, such 
as MCA-induced sarcomas [41].  
The past years were marked by technical advances in flow cytometry and cell 
characterization methods which unveiled the complexity and plasticity of a growing 
number of T cell subsets. For simplification purpose, this thesis will refer to two major 
subsets distinguished by CD4 and CD8 lineage marker expression. Identifying them as 
either CD4+ helper T cells (Th) or cytotoxic CD8+ T cells (CTLs), CD4+ T cells recognize 
immunogenic peptides presented in the context of MHCII, while cytotoxic CD8+ T cells 
recognize immunogenic peptides in the context of MHCI.  
CTLs may apply three distinct mechanisms of killing target cells. Two of these rely on 
cell-cell contact between the effector and the target cell. Firstly, like NK cells, CTLs can 
release lytic granules containing perforin and granzymes into the target cell, inducing its 
apoptosis. Secondly, cell-cell induced apoptosis can be triggered by engagement of Fas 
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ligand expressed on CTLs and Fas receptor (CD95) expressed on the target cell. The third, 
cell-to-cell contact independent mechanism involves cytokine production by CTLs. 
Cytokines such as IFN-γ and TNF-α are being produced following T cell activation. TNF-
α can bind to its corresponding receptor expressed on target cells, inducing target-cell 
apoptosis. In contrast, IFN-γ upregulates expression of MHCI on target cells, increasing 
recognition by CTLs. Moreover, IFN-γ increases Fas receptor expression on target cells, 
facilitating Fas-mediated apoptosis [63]. 
CD4+ Th cells can be classified into a minimum of four classes, Th1, Th2, Th17 and 
regulatory T cells (Tregs) (Th17 will not be further described here; Tregs are described 
in section 5.2.1.3). Critical for orchestrating the adaptive immune response, Th1 and Th2 
subsets can be distinguished according to cytokine production profile and function. Th1 
cells are characterized by IFN-γ and IL-2 production and are responsible for mediating 
the immune response against intracellular pathogens, promoting cell-mediated immunity. 
As described above, IFN-γ is involved in shaping the immune response in multiple ways, 
such as in the activation of macrophages, while production of IL-2 is important for CD4+ 
T cell memory formation and as a stimulus for the activation of CTLs [64]. Th2 cells are 
involved in mediating the immune response against extracellular parasites, promoting 
humoral immunity. Associated with facilitating tumor growth, counteracting Th1 
immunity, Th2 cells produce the cytokines IL-4, IL-5, IL-9, IL-10, IL-13, IL-25 [64].  
According to the importance of T cells in tumor elimination, mice lacking αβ T cells 
(Tcrb-/-) display an increased tumor susceptibility of MCA-induced sarcomas [53]. 
Moreover, the capacity of T cells to recognize specific antigens, using tumor-specific 
antigens for both CD4+ and CD8+ T cell, has been exploited successfully in multiple 
preclinical tumor models and is a strategy for personalized immunotherapy of human 
cancers [65-68]. Aiming to expand pre-existing neoantigen-specific T cell populations 
and to induce a broad repertoire of T cell specificity in cancer patients, clinical trials using 
peptide vaccinations are currently ongoing across multiple types of cancer. For instance, 
a clinical trial is investigating a peptide vaccine containing the neoepitope IDH1 in grade 
III-IV glioma patients that harbor the IDH1R132H-mutation (NCT02454634) [69, 70]. 
 
5.2.1.2. Equilibrium 
Cancer cell variants not eliminated can enter the equilibrium phase. During this phase, 
the immune system exerts sufficient pressure to prevent outgrowth of tumor cells. Tumor 
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control is mainly mediated by T cells, IL-12 and IFN-γ [33, 69]. In contrast, NK cells and 
molecules related to recognition and effector function of the innate arm of immunity are 
not required, indicating that prevention of tumor outgrowth involves adaptive immunity 
only. Notably, in patients, the equilibrium phase can last for decades before residual 
tumor cells enter the final phase of escape [33].  
Experimental evidence for the existence of the equilibrium phase came from experiments 
with a mouse model of primary chemical carcinogenesis [71]. In this study, Koebel et al. 
injected immunocompetent mice subcutaneously (s.c.) with the carcinogen MCA. Even 
though these mice harbored occult cancer cells, they did not develop apparent tumors 
until the immune system was compromised through depletion of T cells and IFN-γ [71]. 
Isolated tumor cells were highly immunogenic, resembling unedited tumor cells from 
MCA-injected immunodeficient Rag2-/- mice. Notably, CD4+ and CD8+ T cells, IL-12 
and IFN-γ, but not cells of the innate immune system were required to prevent tumor 
outgrowth. This observation mechanistically distinguished the elimination and 
equilibrium phase, since the elimination phase requires both innate and adaptive 
immunity [71]. 
 
5.2.1.3. Escape 
The escape phase is characterized by the failure of the immune system to eliminate or 
control transformed cells, resulting in cancer progression, and eventually, a clinical 
malignancy. Due to genetic and epigenetic changes combined with constant immune 
selection pressure, some tumor cell variants can develop mechanisms to grow in an 
immunologically unrestricted manner, circumventing innate and adaptive immunity. This 
process can lead to the emergence of unusually aggressive tumor variants suppressing the 
anti-tumor immune response, for example by loss-of-function of genes involved in the 
MHCI antigen presentation machinery [43]. Thus, mechanisms involved in tumor cell 
escape can be divided into alterations on the tumor cell level, also referred to as intrinsic 
mechanisms, and changes affecting the immune response due to tumor-induced 
immunosuppression also referred to as extrinsic mechanisms including tumor-promoting 
inflammation. 
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Intrinsic mechanisms 
At the tumor cell level, reduced immune recognition and avoidance of immune 
destruction can lead to tumor escape. Reduced immune recognition can result from loss 
of MHC components or defects in the antigen processing function preventing the 
production of peptide and loading to MHC molecules, required for T cell recognition [33, 
72]. Specifically, loss of TAP1, MHCI molecules, β2m, LMP2 and LMP7 favors tumor 
progression [43]. However, also the loss of tumor-specific antigens due to genomic 
instability can prevent detection by antigen-specific CD8+ T cells. Alternatively, shedding 
of NKG2D ligands has been shown to severely compromise the anti-tumor immune 
response leading to immune evasion in individuals with cancer [73]. However, especially 
the development of IFN-γ insensitivity during tumor development has been identified as 
a critical determinant for prevention of T cell-mediated killing and tumor progression. In 
this respect, the study from Kaplan et al. showed complete unresponsiveness to IFN-γ in 
25% of human lung adenocarcinoma cell lines [40]. Moreover, defects in the pathways 
of IFN-receptor signaling have been associated with resistance to PD-1 blockade 
immunotherapy [74]. 
Mechanisms leading to escape from immune destruction can also be a result of defects in 
death-receptor signaling pathways. Resistance to lysis by immune cells can be caused by 
expression of mutated inactive forms of death receptors, such as the TRAIL receptor DR5 
or Fas [43, 75]. In this respect, studies have identified several mutations in TRAIL 
receptors in samples from patients with metastatic breast cancer [75]. Additional 
mechanisms leading to escape from immune destruction are related to the expression of 
antiapoptotic signals. For example, constitutive activation of the pro-oncogenic 
transcription factor STAT3 has been identified to increase tumor cell proliferation, 
survival, and invasion [76]. Alternatively, anti-apoptotic mechanisms induced by 
expression of the cell death inhibiting oncoprotein Bcl-2 promote tumor growth by 
evading immune destruction.  
 
Tumor-promoting inflammation  
In addition to alterations affecting tumor cells themselves, escape can result from the 
generation of an immunosuppressive tumor microenvironment. Tumor-promoting 
inflammation, an enabling characteristic of the hallmark of cancer includes the production 
of cytokines like VEGF, transforming growth factor-β (TGF-β) and indoleamine 2,3-
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dioxygenase (IDO) [33]. Notably, VEGF is not only crucial for angiogenesis but is also 
associated with preventing endogenous DC function. While the highly pleiotropic 
cytokine TGF-β acts as a tumor suppressor in early stages of tumor proliferation, late-
stage expression of TGF-β has been associated with higher tumor grade and poorer 
prognosis [77]. Known to polarize T cells and cells of the monocyte lineage towards an 
immunosuppressive state, TGF-β favors tumor growth by promoting angiogenesis and 
has additionally been associated with sustaining cancer stem cell populations [77, 78]. 
The cytosolic enzyme IDO, produced by macrophages and dendritic cells in response to 
pro-inflammatory factors, is responsible for catalyzing tryptophan degradation producing 
metabolites like kynurenine [77]. Kynurenine is an immunosuppressive factor associated 
with inhibition of T cell effector functions and supports the expansion of regulatory T cell 
(Treg) populations suppressing the immune response [79].  
Recruitment of immunosuppressive cells represents another critical factor in dampening 
anti-tumor immune responses, associated with poorer prognosis. Tregs, CD4+ T cells 
constitutively expressing CD25 and the transcription factors forkhead box (Fox)p3, 
produce immunosuppressive such as cytokines IL-10 and TGF-β upon stimulation. By 
expressing negative co-stimulatory molecules like CTLA-4, PD-1, and PD-L1, Tregs 
actively contribute to an immunosuppressive microenvironment. Moreover, consumption 
of IL-2 by Tregs, a cytokine required for the maintenance of cytotoxic T cell function, 
severely impacts the anti-tumor response [33]. Another immunosuppressive cell type 
involved in supporting tumor growth are myeloid-derived suppressor cells (MDSCs). 
MDSCs represent a heterogeneous group of myeloid progenitor and immature myeloid 
cells that induce Tregs and produce multiple immunosuppressive cytokines including 
TGF-β [80]. Moreover, MDSCs have been implicated in consuming amino acids like 
arginine, tryptophan, and cysteine, essential for proper T cell function [33]. An additional 
myeloid-derived cell type supporting immunosuppression are M2-polarized tumor-
associated macrophages (TAMs). Recruited from peripheral blood, chemokines and 
growth factors induce the differentiation of monocytes into M2-polarized macrophages. 
Factors promoting polarization include cytokines produced by tumor cells (IL-4, IL-10), 
and cytokines produced by cells of the immune system, like Treg-derived IL-10 and Th2-
derived IL-4/IL-13. TAMs contribute to immunosuppression with the production of TGF-
β and IL-10 [81, 82].   
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In summary, the immune system plays a dual role in cancer by suppressing tumor growth 
and selecting tumor cells more fit to evade immune detection. How a tumor-specific 
immune response is generated will be described in the following section. 
 
5.2.2. The cancer-immunity cycle 
Generating an anti-tumor immune response is a multistep process also referred to as the 
cancer-immunity cycle (Figure 4).  
 
Figure 4: The cancer-immunity cycle. The development of an adaptive immune response is a multistep 
process divided into seven steps including antigen release, presentation, priming and activation of T cells, 
trafficking of T cells to tumors, infiltration, recognition, and killing of cancer cells. Adapted from [83]. 
 
Beginning with the release of neoantigens upon cancer cell death, DCs capture and 
process the derived neoantigens (Step 1). During step 2, DCs present captured antigens 
on MHC molecules and migrate to the tumor-draining lymph node. Alternatively, direct 
antigen drainage can occur, leading to neoantigen capture and presentation within the 
tumor-draining lymph node. Presentation of cancer-antigens then induces priming and 
activation of T cells (Step 3). Specifically, activation, expansion, and differentiation 
require the incorporation of three independent signals. Signal one consists of 
immunogenic peptides presented by MHC molecules to the cognate TCR. During signal 
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2, the immunological synapse stabilizes through the interaction of costimulatory 
molecules including but not limited to CD80/CD86 expressed on APCs and CD28 on T 
cells. Signal 3 includes secretion of cytokines by APCs, polarizing T cells towards an 
effector phenotype. IL-12 secreted by APCs induces polarization of Th1 cells, while IL-
4 promotes Th2 differentiation. 
In Step 4, T cells traffic through blood vessels and infiltrate the tumor bed (Step 5). Upon 
recognition of cancer cells, CTLs kill the target cancer cell. The killing of cancer cells 
inducing the release of more neoantigens, which continues the cancer-immunity cycle 
[83]. 
 
5.2.2.1. The immunity cycle in glioma 
Given the regulation of immune cell entry into the CNS by the blood-brain barrier, the 
absence of a conventional lymphatic drainage system and overall low numbers of APCs 
and T cells, the CNS has long been viewed as an immune-privileged site. However, it has 
become increasingly clear that the CNS undergoes constant immune surveillance, being 
capable of orchestrating immune responses involving both innate and adaptive immunity 
[84]. With the discovery of a lymphatic system draining CNS antigens by the 
cerebrospinal fluid into cervical lymph nodes, it is now believed that both egress and entry 
are dynamically regulated [77, 85]. Especially in neurological diseases, immune cells 
readily migrate into the CNS following chemotactic cues. In glioma, the interaction of the 
tumor and immune cells is additionally facilitated with increased VEGF secreted by 
tumor cells, inducing permeability of the blood-brain barrier [84].  
Regarding the cancer-immunity cycle described for glioma, antigens from dying tumor 
cells can be processed by infiltrating macrophages, DCs and CNS-resident microglia. 
Even though microglia can actively contribute to an anti-tumor immune response through 
the release of reactive oxygen species, phagocytosis, presenting antigens and activating 
T cells, they have been described to lose the capacity of expressing MHC molecules in 
high-grade gliomas [77]. In this respect, within the glioma-immunity cycle, DCs are 
believed to migrate through the lymphatic vessels of the meningeal sinuses, priming and 
activating T cells in the cervical lymph nodes. Activated T cells then traffic to the tumor 
site interacting with APCs and tumor cells by migrating through the blood-brain barrier 
and the blood-tumor barrier [84]. 
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However, as described in section 5.2.1.3, tumors exploit multiple mechanisms of immune 
suppression to evade immune destruction. Especially malignant gliomas are characterized 
by inducing profound immunosuppression, both locally and systemically [86].  
 
Concluding, the cancer-immunity provides multiple targets to boost the anti-tumor 
immune response. Examples of current immunotherapy-based strategies aiming to 
overcome glioma-induced immunosuppression will be outlined in section 5.3.3. 
 
5.3. Malignant glioma 
Multiple types of tumors have been identified in the CNS. Among them, malignant 
gliomas represent the most common primary CNS tumor with an incidence of 6 new cases 
per 100´000 individuals per year worldwide [87]. Based on data collected from the years 
2012-2014, the lifetime risk of developing brain and other nervous system cancer has 
been estimated to be approximately 0.6% for men and women [88]. 
Even though gliomas can arise from distinct cell types including neural stem cells, 
astrocytes, or oligodendroglial progenitor cells, the majority of gliomas are astrocyte-
derived [89]. Roughly 50% of newly diagnosed gliomas are classified as glioblastoma, a 
highly malignant brain cancer associated with a median survival of 14-17 months despite 
aggressive treatment consisting of surgical resection, radiotherapy, and chemotherapy. 
The only established environmental risk factor remains ionizing radiation [90]. However, 
multiple familial cancer predisposition syndromes have been associated with increased 
risk of brain cancer. Among them is neurofibromatosis type I (caused by mutations in 
NF1 or NF2), the Turcot syndrome (mutations in genes associated with DNA repair) and 
the Li Fraumeni syndrome (mutations in checkpoint gene TP53) [87, 91]. Additionally, 
polymorphisms in the 3′-untranslated region of IL12A resulting in lower IL-12 production 
has been correlated with an increased susceptibility to develop glioblastomas [92]. 
Non-specific initial symptoms are primarily due to increased intracranial pressure caused 
by tumor growth and include headaches, nausea, and vomiting [93]. Specific symptoms 
depend on the location and encompass seizures (occurring in 25% of patients with high-
grade gliomas), partial weakness of one side of the body or difficulties in memory [24, 
90]. The gold standard for diagnosis is magnetic resonance imaging (MRI), however, also 
computed tomography (CT) provides aid in defining the surgical strategy. Thus far, no 
serum markers have been identified allowing early detection [87].  
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One of the reasons for poor survival is the invasive, diffuse infiltration pattern into 
surrounding tissue, resulting in the inability of complete surgical resection [94]. 
Additionally, tumor heterogeneity contributes to the failure of conventional therapies. 
Analysis of glioblastoma patient samples before and post-treatment revealed variable 
degrees of genetic similarity and acquired mutations typical for recurrent tumors. The 
capacity of developing therapy resistance has been attributed to cancer stem cells, also 
referred to as recurrence-initiating stem-like cancer cells [95]. Several studies supported 
the notion of stem-like cancer cells being crucial for resistance to therapy [96, 97]. 
However, markers defining these cells remain a subject of debate. 
 
5.3.1. Classification and molecular characterization 
Based on the “WHO Classification of Tumors of the CNS” from 2007 [98], gliomas were 
previously exclusively classified according to histological criteria, grouping tumors per 
origin of cell type as astrocytoma, oligodendroglioma or ependymal tumors [94]. 
Additionally, each tumor received a histological grade, reflecting the degree of 
malignancy ranging from slow-growing, surgically curable lesions (WHO grade I) to 
highly malignant, diffusely infiltrating tumors (WHO grade IV). However, especially in 
the context of diffusely infiltrating tumors, this classification system led to considerable 
inter-observer variations [99]. Thus, the revised “WHO Classification of Tumors of the 
CNS” from 2016 included molecular characteristics, enabling a more precise tumor 
characterization and prognosis, as depicted in Figure 5 [100]. 
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Figure 5: Genetic pathways in primary and secondary glioblastomas. Adapted from [101]. 
 
The diagnostic biomarker distinguishing gliomas with distinct biology and clinical 
behavior is based on the presence of mutations in the isocitrate dehydrogenases (IDH) 1 
or 2, discriminating between primary and secondary glioblastomas. Primary 
glioblastomas develop de novo and have a short clinical history of 3-6 months before 
diagnosis. Associated with TP53 and PTEN mutations, this particularly aggressive tumor 
is characterized by significant proliferation, invasion, angiogenesis and is refractory to 
treatment with survival rates of 14-17 months after diagnosis [102]. In contrast, secondary 
glioblastomas develop progressively from WHO grade II tumors. Roughly 90% of WHO 
grade II tumors harbor IDH1/2 mutations, causing aberrant DNA and histone methylation 
[12]. In this respect, mutated IDH1 has been associated with induction of hypoxia-
inducible factor, glucose transporters and increased VEGF production leading to the 
hallmarks of altered energy metabolism and increased angiogenesis [103]. However, 
additional molecular characterization is required to distinguish oligodendrogliomas 
(codeletion of 1p/19q) and diffuse astrocytoma (TP53 mutations), the latter ultimately 
progressing to treatment-refractory WHO grade IV secondary glioblastomas. Notably, 
WHO grade II tumors are not surgically curable anymore and are characterized by 
proliferation and invasion. Even though considered as treatment responsive, patients 
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diagnosed with WHO grade II astrocytomas have a median survival of 5-10 years [102]. 
Within five years, anaplastic astrocytoma (WHO grade III) develop. In addition to 
increased proliferation and invasion, WHO grade III astrocytomas have acquired features 
of angiogenesis. Despite lower survival rates of 2-3 years, grade III astrocytoma remain 
treatment responsive. Nevertheless, within two years, anaplastic astrocytoma can develop 
into treatment refractory, secondary glioblastomas (WHO grade IV). 
Predictive biomarkers for therapy include O6-methylguanine-methyltransferase (MGMT) 
promoter methylation. The MGMT gene encodes for a DNA repair protein, which 
removes alkyl products from the O6 position of guanine. Epigenetic silencing leading to 
loss of gene transcription and reduced protein expression has been correlated with 
increased sensitivity to alkylating chemotherapeutics like temozolomide (TMZ). Notably, 
75% of secondary glioblastoma and 36% of primary glioblastoma (IDH wild-type) are 
characterized by this promoter methylation [104].  
 
5.3.2. Current treatment for glioma 
The current standard of care for gliomas includes surgery, radiotherapy, and 
chemotherapy. Decisions in treatments are based on tissue diagnosis and identification of 
molecular markers, the age of the patient and Karnofsky performance (classifying patients 
based on functional impairment). Additionally, before surgery patients frequently receive 
corticosteroids, especially dexamethasone, to decrease tumor-associated edema [84, 87].  
Surgeries aim for maximal safe resection using tools such as surgical navigation systems 
with functional MRI datasets and the fluorescent dye 5-aminolevulinic acid to visualize 
tumor tissue. Electromyography in patients under local anesthesia is performed when 
tumors reside in areas where resection may cause permanent neurological deficits [87].  
Radiotherapy as a backbone of standard treatment after surgery is used in the treatment 
of newly diagnosed and recurrent glioblastoma and aims to improve local tumor control 
and overall survival. However, even though improvement of survival rates has been 
shown for every tumor grade, no patients have been cured with this treatment modality 
[94]. Due to the unmasking of tumor antigens induced by radiotherapy, it has been 
suggested that radiotherapy combined with immune checkpoint inhibition might have a 
synergistic effect. Supported by preclinical results [105], currently running clinical trials 
will show whether the combination of radiotherapy and immune checkpoint inhibition 
will also improve patient survival (see in section 5.3.3) [84].  
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Together with radiotherapy, cytotoxic chemotherapy using the DNA alkylating agent 
TMZ represents the gold standard of treatment for most patients with glioma. As 
described in section 5.3.1, it requires assessment of MGMT-promotor methylation as a 
predictive biomarker, since tumor cells expressing low to absent MGMT levels are more 
sensitive to TMZ treatment [106]. However, tumors with MGMT-promotor methylation 
can acquire mutation-driven secondary TMZ resistance [107]. Dose-limiting toxicity of 
TMZ results from myelosuppression, especially leukopenia and lymphopenia and might 
cause treatment delay, reduction or initiation of alternative treatments [84]. Other 
chemotherapeutic treatments use nitrosourea-based compounds, such as carmustine. 
Local delivery of carmustine wafers (Gliadel®) implanted into the surgical cavity has 
previously been approved by the FDA for intracerebral chemotherapy of malignant 
glioma [108]. However, leading to modest survival advantages and poor efficacy with 
newly diagnosed WHO grade III, IV, or recurrent gliomas, carmustine wafers are rarely 
considered for therapies nowadays [87].  
In cases of progressive disease despite prior therapy, patients can be treated with 
bevacizumab, an antibody inhibiting the activity of VEGF. However, this anti-angiogenic 
drug has only been approved in some countries, for instance, the United States and 
Switzerland, since lack of a controlled trial prevented approval in the European Union 
[109]. 
  
5.3.3. Prospects of immunotherapeutic approaches 
Despite current standard of care, glioblastoma ultimately relapses in almost all patients 
[84]. No standard treatment can currently prolong survival in these patients, underlining 
the unmet need for continuous development of therapies. Due to the success of 
immunotherapy with immune checkpoint inhibitors for the treatment of other tumor 
types, immunotherapy has become an appealing strategy for glioblastoma [84, 110-115]. 
Justified by several promising preclinical datasets, multiple studies have been performed 
investigating distinct molecules and combinations. 
Studies activating co-stimulatory receptors (e.g., OX-40) or blocking of co-inhibitory 
receptors (e.g., PD-1 and CTLA-4) have been shown to induce anti-tumor responses 
leading to prolonged survival in distinct preclinical glioma models [84, 105, 116, 117]. 
Moreover, combinations aiming to overcome immunosuppression and to increase effector 
to Treg ratio in the tumor microenvironment have led to long-term survival. Among the 
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combinations evaluated are triple therapies consisting of IDO, CTLA-4, and PD-L1 [118], 
combinations of immune checkpoint inhibition with radiotherapy [105, 119] and the 
combination of local pro-inflammatory cytokine release with CTLA-4 blockade [120]. 
As 88% of newly diagnosed glioblastoma patient samples and 72% of recurrent 
glioblastoma patient samples stain positive for PD-L1, this led to the initiation of many 
clinical trials blocking this axis, as exemplified in Table 1 [84, 121-123]. Unfortunately, 
no results are available from these studies so far, but the PD1/PD-L1 axis may play a 
prominent role in glioblastoma. 
 
Other strategies to revert the glioma-associated immunosuppression into a potent anti-
tumor immune response rely on vaccine-based immunotherapeutic approaches. Target 
antigens may be predefined tumor-associated antigens, a personalized panel of tumor-
associated antigens, an unbiased antigen selection using undefined tumor-derived 
peptides or whole tumor cell lysates [124]. Alternatively, vaccines can target tumor-
specific mutant proteins like the epidermal growth factor receptor (EGFR) variant III 
(EGFRvIII), which is frequently amplified in IDH wild-type glioblastomas [124-126]. 
Initial promising results were obtained in three uncontrolled phase II trials leading to 
progression-free and overall survival improvement for patients with resected tumors 
without progression after chemoradiotherapy [124, 127-129]. However, a later conducted 
phase III trial with newly diagnosed glioblastoma trial (ACT-IV) had to be terminated 
since no improvement of overall survival was achieved [130]. 
 
Based on current knowledge, overcoming the glioma-associated immunosuppression 
remains a significant obstacle and likely requires the combination of several 
immunomodulatory agents. In this regard, further results from preclinical studies will 
support decisions on which combinations can increase therapeutic activity. 
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Table 1: Overview of initiated clinical trials for primary brain tumors and brain metastases targeting 
the PD-1/PD-L1 axis. (Registered on clinicaltrials.gov; status 18/09/2017) [131, 132].  
Registration 
number 
Agents 
tested 
Therapy Tumor Phase Status 
NCT02374242 
anti-PD-1, 
anti-
CTLA-4 
Nivolumab + 
Ipilimumab 
Melanoma; 
Brain Metastases 
II 
Active, not 
recruiting 
NCT02621515 
anti-PD-1, 
anti-
CTLA-4 
Nivolumab + 
Ipilimumab 
Melanoma; 
Brain Metastases 
II Recruiting 
NCT02978404 anti-PD-1 
Nivolumab + 
Radiosurgery 
Metastatic Renal Cell C
arcinoma; Non-
Small Cell Lung Cancer
 Meta-static; 
Brain Metastases 
II Recruiting 
NCT02669914 anti-PD-L1 Durvalumab 
Brain Metastases from 
Epithelial-Derived 
Tumors 
II Recruiting 
NCT01952769 anti-PD-1 Pidilizumab Diffuse pontine gliomas I + II 
Active, not 
recruiting 
NCT02529072 anti-PD-1 
Nivolumab + 
Surgery + DC 
Vaccination 
Malignant Glioma; 
Astrocytoma; 
Glioblastoma 
I Recruiting 
NCT02658981 
anti-LAG3 
+ anti-PD-1 
 Urelumab + 
Nivolumab 
Glioblastoma; 
Gliosarcoma; 
Recurrent Brain Neopla
sm 
I Recruiting 
NCT02852655 anti-PD-1 Pembrolizumab 
Recurrent/Progressive 
Glioblastoma 
 
Active, not 
recruiting 
NCT02335918 
anti-CD27 
+ anti-PD-1 
Varlilumab + 
Nivolumab 
Glioblastoma II 
Not 
recruiting 
NCT03058289 anti-PD-1 
INT230-6 + anti-
PD-1 antibody 
Melanoma; 
Head and Neck Cancer; 
Lymphoma; 
Breast Cancer; 
Pancreatic Cancer; 
Liver Cancer; 
Colon Cancer; 
Lung Cancer; 
Glioblastoma 
I + II Recruiting 
NCT01860638 anti-VEGF 
Bevacizumab + 
Lomustine + 
Radiotherapy + 
Temozolomide 
Glioblastoma II Completed 
NCT03174197 
Anti-PD-
L1 
Atezolizumab + 
Radiotherapy + 
Temozolomide 
Newly diagnosed 
glioblastoma 
I + II Recruiting 
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5.3.4. Experimental glioma models 
Choosing appropriate rodent models is crucial for studying treatment approaches. An 
ideal glioma model should combine several features including the recapitulation of human 
disease characteristics of invasion and angiogenesis, the possibility of genetic 
modification, being reproducible and having predictable growth patterns [133]. Currently, 
several preclinical glioma models are being used to investigate the interaction of tumor 
cells with the CNS and infiltrating immune cells. Classified into xenograft, allograft, and 
spontaneous transgenic models, examples of each will be described below.   
One of the frequently used xenograft glioma models is the U251 malignant glioma cell 
line originally derived from a 75-year-old male with glioblastoma [134]. Injected 
intracranially into SCID mice, this mouse model recapitulates characteristics of 
glioblastoma such as the infiltrative pattern of invasion into normal brain parenchyma 
[135]. Histochemical analysis showed similarities to human glioblastoma, as tumor cells 
were positive for glial fibrillary acidic protein (GFAP), vimentin and S100B [135-138]. 
Genetically, the U251 cell line has been shown to possess key features resembling human 
glioblastoma, for instance, a dysfunctional mutant tumor suppressor TP53 and deletions 
in the cell cycle suppressor genes p14ARF and p16 [135, 138]. A significant drawback, 
however, in using xenograft models like the U251 malignant glioma model is that it does 
not recapitulate the interaction of immune cells with tumor cells of human glioblastoma, 
arguing for a shift away from xenograft models for immunotherapy approaches. 
Allograft models used as preclinical glioma models can be induced by chemical induction 
to generate a stable transplantable cell line such as the astrocyte-derived GL-261 cell line 
[139] (further described in section 5.3.4.1) or derived from spontaneously developing 
tumors. A frequently used cell line from a spontaneously developed glioma derives from 
the VM mouse strain obtained through homogenization of the tumor tissue and several in 
vitro and in vivo passages [135, 140]. Resembling anaplastic astrocytoma, the derived 
SMA-560 cell line is characterized by low S-100 expression and high GFAP expression 
[135, 141]. Moreover, SMA-560 cells express TGF-β, an immunosuppressive factor 
secreted in human glioblastoma [142]. Notably, the SMA-560 tumor model has been used 
for several studies of immunotherapy applications. For instance, genetically modified T 
cells expressing chimeric antigen receptors binding to the EGFRvIII led to abrogation of 
tumor growth and conferred immunological memory [143].  
  28 
 
In addition to allograft and xenograft glioma models, several transgenic models leading 
to spontaneous glioma development have been generated. The first transgenic 
astrocytoma model was developed in 1995, inducing expression of the pro-tumorigenic 
SV40 large T antigen in astrocytes under the control of the GFAP promoter [144]. Other 
transgenic mouse models were generated taking key genetic alterations involved in 
primary and secondary glioblastoma initiation or progression into account, such as 
deficiency in the tumor suppressor TP53. In this respect, deficiency in TP53 specifically 
in astrocytes promotes the formation of high-grade gliomas in mice that simultaneously 
express the HRasV12 oncogene [145-147]. However, whether the interaction between 
immune cells and tumor cells is recapitulated in these mice remains to be investigated. 
 
5.3.4.1. The GL-261 glioma model 
One of the most commonly used rodent glioma models in the context of immunotherapy 
studies for the treatment of glioblastoma is the orthotopic GL-261 tumor model. This 
astrocyte-derived GL-261 tumor cell line was initially made through intracranial 
injections of MCA into the brains of mice [139] and is a syngeneic mouse model in 
C57BL/6 mice.  
GL-261 tumor cells carry distinct oncogenic alterations in genes associated with human 
carcinogenesis, such as increased expression of the Myc oncogene and inactivation of the 
tumor suppressor p53  [135, 148]. Moreover, the GL-261 cell line carries a point mutation 
in the K-Ras gene [149]. 
Additionally, GL-261 tumor cells have been characterized to express basal levels of 
MHCI, which can be increased with IFN-γ [149]. Moreover, IFN-γ can also induce 
MHCII expression. In contrast, overexpression of other cytokines did not affect MHCI or 
MHCII expression [120, 149]. Furthermore, GL-261 tumor cells express basal levels of 
the costimulatory molecules CD80 and CD86, classifying GL-261 tumor cells as 
moderately immunogenic [150].  
Tumor antigens identified include the murine homolog AN2 of the human melanoma 
proteoglycan and the glioma antigen GARC-1 for cytotoxic lymphocytes [150-152]. 
Additionally, it has been shown that GL-261 tumor cells express the shared melanoma 
antigens glycoprotein (gp)100, tyrosinase-related protein 2 (TRP-2) and the receptor 
tyrosine kinase  EphA-2 [153, 154]. 
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Unlike spontaneous glioma, GL-261 tumor cells display a radial growth pattern and upon 
injection, tumor cells form small islets scattered around the injection site [150]. Injected 
into the right striatum, 100 cells were found to be sufficient for mice to reach withdrawal 
criteria within 70 days [149]. However, for studies using the GL-261 tumor model, the 
number of injected cells varies between 1 x 104 and 13 x 104 cells [105, 120]. 
 
Immunotherapy approaches in the GL-261 tumor model 
Multiple approaches have been investigated with the GL-261 tumor model. These include 
adoptive T cell transfers, monoclonal antibodies directed against relevant immunological 
targets such as CTLA-4, active immunotherapy with dendritic cells loaded with tumor 
antigens, gene therapy using genetically modified tumor cells together with in situ gene 
therapy and studies involving overexpression of cytokines [150]. 
Regarding adoptive transfer setups, 30 million TILs together with systemic administration 
of IL-2 and local tumor irradiation led to tumor rejection in 15% of treated animals [155]. 
In contrast, sub-lethal whole body irradiation combined with 10 million total effector T 
cells led to a complete rescue of mice [156]. 
Treatment approaches using monoclonal antibodies for boosting the anti-tumor immune 
responses have been shown by enhancing co-stimulatory signaling through OX-40 and 
41-BB [150]. Moreover, blockade of CTLA-4 in combination with IL-12 significantly 
improved the anti-tumor immune response leading to 80% of tumor rejection [120]. Also, 
systemic inhibition of TGF-β combined with peptide-based vaccination against known 
glioma-associated antigen led to the prolonged survival of mice [157]. Other approaches 
targeting the immune checkpoint surface receptor PD-1, in combination with radiation 
led to 25% survival of mice [105]. 
Vaccination experiments were performed by several groups using whole cell, whole 
tumor antigen, and antigen-specific approaches. Notably, preventive treatment leading to 
50% of protection of tumor growth in mice was achieved by loading DCs with total GL-
261 RNA lysate, underlining the immunogenicity of the GL-261 cell line [158]. Whereas 
in established GL-261 tumors, DCs fused with tumor cells, local radiation and systemic 
treatment with anti-OX40 antibodies were required to induce protection against glioma 
[159]. Moreover, the requirement of Treg elimination for successful treatment of mice 
with tumor lysate-pulsed DCs has been previously established [160]. Vaccinations with 
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the immunodominant peptides gp100 and TRP-2 were found to be sufficient to induce 
tumor protection in 80% of mice [153]. 
Gene therapy approaches aiming to increase the immunogenicity of tumor cells by 
inducing overexpression of distinct cytokines have mainly focused on the cytokines GM-
CF, IL-2 and IL-12 (preclinical models used with IL-12 overexpressing tumor cells will 
be described in section 5.4.2 and 5.4.2.1). In this respect, mice treated with IL-2 secreting 
fibroblasts and oral treatment with the chemotherapeutic pioglitazone prolonged survival 
of mice [161]. Immunization with tumor cells overexpressing GM-CSF improved 
survival of mice and was found to synergize with whole body irradiation leading to 40-
80% tumor protection [162, 163]. 
In summary, the GL-261 tumor model has been used extensively for the investigation of 
immunotherapy approaches, leading to several advances in experimental immunotherapy 
for the treatment of glioblastoma.   
 
5.4. The IL-12 cytokine family 
The IL-12 cytokine family consists of the four heterodimeric cytokines IL-12, IL-23, IL-
27, and IL-35. One of the distinctive features of the IL-12 cytokine family is the chain 
sharing of cytokines and receptors. However, despite structural similarities, cytokines, 
and receptors of the IL-12 family shape the outcome of immune responses in distinct 
ways, having both pro-inflammatory and inhibitory effects (Figure 6) [164]. 
 
Figure 6: The IL-12 cytokine family. Cytokines with their respective receptor subunits and associated 
JAK-STAT signaling. Adapted from [164]. 
 
The pro-inflammatory cytokine IL-12, identified in 1989 as a natural killer cell 
stimulatory factor, has a molecular weight of 70kDA and consists of the disulfide-linked 
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light p35 subunit and the heavy p40 subunit [165]. While the p40 subunit is expressed in 
abundance, the p35 subunit is constitutively expressed at low levels [166]. However, only 
co-expression of both subunits can induce biologically active IL-12. Binding of IL-12 to 
the IL-12Rβ1 and IL12Rβ2 subunits generates Th1 responses by signaling through 
STAT4 (IL-12 mechanism of action will be described in section 5.4.1) [167]. 
IL-23 shares the p40 subunit with IL-12 but forms the functional IL-23 cytokine together 
with the disulfide-linked p19 subunit. IL-23 produced by DCs, monocytes, macrophages 
and B cells is known to act on memory T cells, NK cells, Th1 and Th17 expressing the 
functional receptor composed of the IL-12Rβ1 and IL-23R subunits. Signaling through 
STAT3 and STAT4, IL-23 signaling is involved in Th1 activation and Th17 polarization 
and activation [164]. 
The IL-12 family member IL-27 consists of the subunits p28 and the Epstein-Barr virus-
induced gene 3 (EBI3). Major sources of IL-27 are macrophages, inflammatory 
monocytes, and DCs, while plasma cells, endothelial cells, and epithelial cells are 
considered as minor sources of IL-27 [168, 169]. Expression of IL-27 has been associated 
with the resolution phase of an autoimmune response [164, 170, 171]. The functional IL-
27 receptor is composed of gp130 and the IL-27Rα (WSX-1), expressed by NK cells, 
CD4+ and CD8+ T cells. Signaling through STAT1 and STAT3, IL-27 inhibits the 
development of Th17 cells and promotes IL-10 producing regulatory T cells. Together 
with IL-12, IL-27 can support the production of IFN-γ by T and NK cells, supporting pro-
inflammatory responses [164]. Due to its context-dependent influence on both pro-and 
anti-inflammatory immune reactions, IL-27 is thus considered to have an 
immunoregulatory role [164]. 
IL-35 is composed of the subunits p35 and EBI3, while the receptor has been suggested 
to consist out of the IL12Rβ2 and gp130 or IL27Rα subunits [164]. Produced by Tregs, 
IL-35 has been proposed to inhibit T cell responses and to convert naïve T cells into Tregs 
by signaling through STAT1 and STAT4 [172]. However, with a recently retracted 
publication regarding Tregs requiring IL-35 for immune suppression [173], the induced 
mechanisms of IL-35 remain a subject of debate. 
 
5.4.1. Mechanism of IL-12 action 
Produced by antigen presenting cells such as dendritic cells, IL-12 can activate and induce 
proliferation of IL-12 receptor expressing ILCs, NKT, and T cells. Thus, IL-12 has been 
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attributed to link innate and adaptive immune responses. IL-12 signaling further leads to 
polarization of a Th1 immune response, suppressing Th2 immunity. The primary cytokine 
produced upon IL-12 signaling is IFN-γ, which acts on APCs and induces increased 
expression of IL-12. However, IL-12 may also trigger the release of other cytokines such 
as TNF-α, GM-CSF, and IL-2 [166]. Importantly, IL-12 signaling is known to induce 
cytotoxicity mediated by the release of lytic granules containing perforin and granzymes 
into a target cell. Moreover, IL-12 can have an anti-angiogenic effect by triggering the 
production of interferon-inducible protein 10 (IP-10), an inhibitor of neovascularization 
[174]. 
Apart from the established IL-12 receptor expression on ILCs, NKT and T cells, cells of 
myeloid cells origin and tonsillar B cells have previously been shown to express the IL-
12 receptor [175, 176]. In an experimental model of vesicular stomatitis virus (VSV) 
infection of the CNS, enhanced recovery has been found to be mediated by neurons 
expressing the IL-12 receptor [177]. In this respect, also microglia have been shown to 
express the IL-12 receptor in primary culture conditions upon stimulation with IL-12 
[178, 179]. Moreover, IL-12 signaling in keratinocytes has been shown to induce a tissue-
protective response in the Aldara-induced psoriatic plaque formation model [180]. 
 
5.4.2. IL-12 in preclinical tumor models 
The tumor-protective role of IL-12 has been established for both the cytokine and the 
receptor. Mice lacking the p35 subunit display increased numbers of chemically induced 
papillomas and increased incidence of N-methyl-N-nitrosourea-induce T cell lymphomas 
[166, 181, 182], while the lack of the p40 subunit led to accelerated growth of MCA-
induced sarcomas [183]. The absence of IL12Rβ2 subunit expression has been shown to 
predispose to malignancy increasing the incidence of spontaneous tumors and 
accelerating the growth of transplantable tumors [184].  
Preclinical models investigating the anti-tumor immune response induced by IL-12 
include the B16 melanoma model, the CT26 colon carcinoma model, the TSA mammary 
carcinoma model and the 4T1 breast cancer model amongst others (IL-12 in preclinical 
glioma models will be described in section 5.4.2.1). However, its mechanism of action 
has been shown to differ among tumor models. Factors influencing tumor-rejection are 
dose, timing, and location of IL-12 release/injection. In the B16 melanoma model, 
overexpression of IL-12 in tumor cells led to tumor suppression mediated by a subset of 
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Rorγt-dependent innate lymphoid cells [185, 186]. While other studies using established 
s.c. B16 tumors and i.p. injection of IL-12 led to a CD8+ T cell-dependent tumor rejection 
[187]. In contrast, increasing the dose of IL-12 for the treatment of established B16 tumors 
required NK and NKT cell-dependent mechanisms of tumor suppression [183, 188].  
The transplantable BALB/c colon carcinoma CT26 model has also been extensively used 
within IL-12 treatment approaches. However, IL-12 given systemically did not have any 
effect on the s.c. injected primary tumor, most likely due to the absence of responding 
cell types [189]. In contrast, it has been shown that IL-12 significantly reduces liver 
metastasis, a mechanism most likely involving liver-resident NKT cells  [190]. When 
CT26 tumor cells were modified to overexpress IL-12, inhibition of tumor take and tumor 
rejection were dependent on the level of IL-12 expression. Amounts of IL-12 in the pg 
range led to delayed tumor onset and reduced number of lung metastasis upon s.c. and 
i.v. injection [189]. However, tumors were only rejected when simultaneous depletion of 
CD4+ T cells was performed, presumably due to IL-12 receptor expression on regulatory 
T cells [191]. In contrast, amounts of IL-12 released by CT26 in the ng range did not form 
tumors, unless injected cell numbers were increased to 10-50 fold of the minimal lethal 
dose of the parental CT26 cell line [189]. Interestingly, this mechanism was found to be 
IFN-γ independent but required GM-CSF production by CD4+ T cells for tumor rejection 
[192].  
The TSA cell line, initially derived from a spontaneous mouse mammary carcinoma, has 
been modified to overexpress distinct cytokines, amongst which IL-12 was found to be 
the most potent in inducing tumor protection [193, 194]. This mechanism was dependent 
on cytotoxic CD8+ T cells secreting IFN-γ [195]. In the 4T1 tumor model, considered to 
be a less immunogenic model for breast cancer, IL-12 did not affect the primary tumor 
but induced a significant reduction of lung metastasis. This mechanism was found to be 
partially dependent on IFN-γ-producing NK cells [166, 196-198]. 
 
5.4.2.1. IL-12 in preclinical glioma models 
Regarding preclinical models for glioma, IL-12 mediated glioma rejection has been 
claimed to be T cell and NK cell-dependent [120, 199-205]. Strategies in delivering IL-
12 include systemic administration, intratumoral delivery, viral transfer systems and cells 
overexpressing IL-12. 
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Early studies with a GL-26 glioma model and intratumoral administration using 
adenoviral delivery of IL-12 at day four post tumor cell injection led to the survival of 
50% of mice accompanied by the infiltration of CD8+ and CD4+ T cells [199]. However, 
these studies lacked functional experiments showing the necessity of T cells for the anti-
tumor immune response [199]. Injection of neural stem cells expressing IL-12 on day two 
post tumor cell injection only led to tumor rejection in 20% of mice. Here, IL-12 led to 
an influx of T cells. However, this study also lacked functional data to undermine the 
requirement of T cells for tumor rejection [200]. In another C57BL/6 model, mice were 
injected i.c. with 203 glioma cells. In this study, treatment consisted of systemic injection 
of IL-12 and IL-18, together with vaccination of dendritic cells pulsed with Semliki Forest 
virus (SFV) and 203 glioma cDNA [201]. Here, tumor rejection was induced in a T and 
NK cell-dependent fashion and required IFN-γ [201].  
In the GL-261 tumor model, an approach of using concentrated DNA/PPC 
(polyethylenimine covalently modified with methoxypolyethyleneglycol and cholesterol) 
complexes delivering a murine plasmid encoding IL-12 (pmIL-12) in combination with 
biodegradable carmustine (BCNU) chemotherapy led to survival in 40% of mice [202]. 
Moreover, Vetter et al. used the GL261 glioma cell model and injected cells into the 
cerebellum of transgenic mice that constitutively expressed IL-12 under the control of the 
GFAP promoter in astrocytes, leading to mainly CD8+ T cell-dependent glioma rejection  
[203]. Our lab has previously shown that local IL-12 delivery combined with systemic 
blockade of the co-inhibitory receptor CTLA-4 in the GL-261 tumor model leads to tumor 
rejection in 80% of mice when initiating treatment at day 21 post tumor cell injection. 
Moreover, tumor rejection was T cell- and perforin-dependent and elicited immunological 
memory [120].  
In studies using a recombinant adeno-associated virus (rAAV) as a vehicle for local 
delivery of IL-12 in athymic mice bearing DBTRG gliomas, tumor rejection was found 
to be NK cell-dependent [204]. In a follow-up study, the mechanism was further 
complemented in that tumor rejection required the activation of microglia expressing 
TRAIL [205]. Another recent approach used oncolytic herpes simplex virus (HSV) 
delivering angiostatin (G47Δ-mAngio) and IL-12 (G47Δ-mIL12). Angiostatin, a potent 
inducer of tumor vasculature regression co-delivered with IL-12, significantly prolonged 
survival of mice bearing U87 gliomas [206]. While a recent study implicated the 
importance of macrophages in a triple treatment setup of anti-CTLA-4, anti-PD-1 and 
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G47Δ-mIL12 in a glioblastoma stem-like cell model (GSC005), leading to tumor 
rejection in 50% of mice [207]. 
In summary, the anti-tumorigenic effects of IL-12 are not only tissue-specific but are also 
time- and dose-dependent, leading to the involvement of distinct responsive effector cell 
subsets. 
 
5.4.3. IL-12 for the treatment of human cancer 
The success of IL-12 obtained in preclinical tumor models prompted the translation into 
clinical settings. The applied approaches for the treatment of human cancer with IL-12 
can be divided into three distinct groups. Firstly, administrating IL-12 alone or in 
combination with chemotherapy or monoclonal antibodies. Secondly, vaccine-based 
approaches based on tumor antigen-derived peptides in combination with IL-12. Thirdly, 
gene delivery systems and adoptive cell transfer systems [208]. 
Most of the studies performed between 1996 and 2005 aimed to assess safety evaluations 
of IL-12 and were based on active, non-specific IL-12 therapy. Administered either i.v. 
or s.c., patients with distinct cancers, such as metastatic renal carcinoma or melanoma, 
were treated with IL-12 only or in combination with other treatment approaches [166, 
209-217]. Promising results were obtained in hematological cancers such as refractory 
non-Hodgkin`s B-cell lymphoma when IL-12 was combined with rituximab, having 11 
complete responders and 18 partial responders out of 43 participants [218]. For solid 
cancers, however, response rates were low throughout different types of cancers using IL-
12 alone but also when used in combination with other treatment approaches. For 
instance, a complete response was achieved in only one out of 12 enrolled melanoma 
patients injected i.v. with IL-12 [209]. Moreover, only one out of 51 advanced renal cell 
carcinoma patients injected s.c. with IL-12 displayed a complete response, while 34 
patients had stable and 14 patients progressive disease [213]. Combinatorial approaches 
for patients with metastatic Her2+ breast carcinoma using i.v. and s.c. injected IL-12 
together with the chemotherapeutic paclitaxel and trastuzumab resulted in only one 
complete responder out of 21 enrolled patients [217]. Importantly, not only the low 
response rates but the occurrence of adverse side effects due to toxicity leading to 
fatalities abrogated the pursuit of systemic IL-12 therapy [209, 216]. 
After years of discouragement, there has been a regain of interest for the administration 
of IL-12 for cancer treatment with the focus on local instead of systemic delivery, aiming 
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to minimize toxicity while maximizing efficiency [166, 209, 210, 216]. In this respect, 
there has been an increase in registered clinical trials since 2011 on clinicaltrials.gov, 
using local delivery systems for IL-12 [208]. Strategies for local delivery include 
nanoparticle-based systems, immuno-cytokines (IL-12 fused to tumor targeting 
antibodies), viral delivery and gene therapy approaches [219-225]. Moreover, another 
approach being investigated uses chimeric antigen receptor (CAR)-modified T cells 
engineered with the IL-12 gene [208, 226].  
Currently registered clinical trials mainly focus on gene delivery systems, e.g., using in 
situ electroporation of plasmids encoding for IL-12 in different cancer types. In this 
respect, the clinical trials treating melanoma, cutaneous T-cell lymphomas and Merkel 
cell carcinoma patients have been completed. However, results are not available yet 
([166], NCT01502293, NCT01440816, NCT01579318). Studies using the immuno-
cytokine NHS-IL12 (construct composed of two IL-12 heterodimers fused to the NHS76 
antibody recognizing single-and double-stranded DNA and thereby necrotic areas of the 
tumor [227]) are still recruiting. 
Regarding glioma, three clinical trials using IL-12 therapy are currently registered with 
clinicaltrial.gov (status 07/09/2017). A study treating high-grade glioma based on 
dendritic cells expressing IL-12 loaded with autologous tumor lysate in combination with 
standard therapy (surgery, temozolomide, and radiotherapy) has recently been completed 
(NCT01213407, [228-230]). The other two registered clinical trials use viral delivery 
systems, either an engineered HSV-1 expressing IL-12 (NCT0206282, recruiting 
patients) or an adenovirus vector engineered to express IL-12 (NCT02026271). First 
results of the latter trial, treating patients diagnosed with recurrent or progressive glioma 
with a combination of an adenoviral vector delivering IL-12 under the control of an orally 
given activator ligand (veledimex) were presented at the ASCO 2016 meeting. Peripheral 
blood samples had an increase of CD8+ T cells and an increased ratio of effector-to-
suppressor T cells (CD8+/FoxP3+). Moreover, patients displayed minimal but manageable 
neurotoxicity [231]. 
In summary, multiple clinical trials for the treatment of human cancers with IL-12 are 
currently ongoing. Given the toxicity-related issues in early clinical trials, current 
strategies aim to minimize toxicity, while maximizing efficacy with intratumoral 
administration instead of systemic delivery of IL-12. 
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6. Aim of the study 
Glioblastoma is the most malignant type of brain cancer with patients having a median 
survival of 15-17 months, despite therapy consisting of maximal surgery, radiotherapy, 
and chemotherapy. The poor prognosis of this cancer type underlines the unmet medical 
need driving the development of new treatments. Given the success of immunotherapies 
in other tumor types where conventional therapies provided limited success, there is 
considerable interest in developing immunotherapies for the treatment of glioblastoma.  
We previously showed that immunomodulation by reverting the suppressive tumor 
microenvironment into a pro-inflammatory microenvironment can lead to glioma 
rejection [120]. Using the C57BL/6 syngeneic GL-261 glioma model, with GL-261 tumor 
cells continuously releasing the proinflammatory cytokine IL-12 and firefly (Photinus 
pyralis) luciferase for monitoring tumor development by bioluminescence imaging, we 
identified that IL-12 mediated glioma rejection involves T cells, but not NK cells, is 
perforin-dependent and IFN-γ-independent. However, translation of this knowledge into 
the human situation for the development of new therapies requires an immunological 
understanding of the mechanistic underpinnings, including the characterization of directly 
and indirectly affected cells. Thus, the objective of this study was to investigate the 
mechanism of IL-12 in triggering tumor rejection by studying the contribution of: 
 
1.) the CNS-resident cells versus hematopoietic-derived cells regarding their 
requirement of responding to IL-12 
 
2.) IL-12 in the context of the glioma immune-cycle by studying the contribution of 
intratumoral versus lymph node immune responses, including tracking of tumor-
specific T cells and investigating the involved antigen presenting cell types.
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7. Disclaimer 
This thesis was based upon and partly adapted from the following manuscript: 
 
” IL-12 mediated glioma rejection relies on local responsiveness of CD8+ T 
cells” 
 
Vrohlings M, Tugues S, Haftmann C, Leung B, Sassi A, Jaberg J, Becher B. manuscript 
in preparation. 
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8. Materials and methods 
Animals. C57BL/6 mice were obtained from Janvier, and congenic C57BL/6-CD45.1 
and CD45.1/2 bred in-house; ccr2-/- on a C57BL/6 background were kindly provided by 
L. Borsig (University of Zurich, Zurich, Switzerland). IL12rb2-/-, Rag1-/- mice were 
purchased from Jackson Laboratories. OT1 and OT2 mice bred on the C57BL/6 
background were kindly provided by M. van den Broek (University of Zurich, Zurich, 
Switzerland) and the Laboratory Animal Science Center (LASC) of the University of 
Zurich. Batf3-/- mice were kindly provided by M. Suter (University of Zurich, Zurich, 
Switzerland). 
In most experiments, mice at 7-12 weeks of age were used. All animals were kept in-
house consistent with institutional guidelines under specific pathogen-free conditions 
with food and water provided ad libitum at a 12-h light/dark cycle. All experiments were 
performed according to institutional guidelines and approved by the Swiss cantonal 
veterinary office (licenses 65/2012; 25/2015). 
 
Murine tumor cell lines. All cell lines (GL-261luc:Fc, GL-261luc:IL12Fc and GL-
261luc:cOva) were maintained at 37°C, 10% CO2 in DMEM supplemented with 10% 
FBS, 1%P/S. As previously described, GL-261 tumor cells were modified to continuously 
release a fusion protein of the proinflammatory cytokine IL-12 joined with the 
crystallizable fragment of IgG3 (IL12Fc) or only the IgG3 (Fc) fragment as a control. 
Moreover, cells were modified to express Photinus pyralis luciferase (GL-261luc) for 
monitoring tumor bioluminescence imaging (BLI) and kept under antibiotic selection 
[120]. 
The generation of GL-261luc with stable expression of chicken ovalbumin (GL-
261luc:cOva) was induced by lentiviral transduction. In brief, lentiviral particles were 
generated by transfecting 293T cells with the packaging constructs psPAX2 and pVSV 
(a kind gift from L. Wong, University of Zurich, Zurich, Switzerland) and the relevant 
lentiviral plasmid. The chicken ovalbumin sequence was cloned into the pLenti CMV 
Blast DEST backbone (Eric Campeau (Addgene plasmid # 17451). The complete 
construct pLenti CMV Blast DEST cOVA was a kind gift from M. van den Broek. GL-
261luc cells expressing chicken ovalbumin were kept under antibiotic selection using 
blasticidin (invivogen). 
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Stable production of IL-12Fc was achieved by lentiviral transduction with the plasmid 
SFG IL12 IL12Fc I2 dCD8 (a kind gift from Sergio Quezada, University College London, 
London). Cytokine production was detected by ELISA (OptEIA mouse IL-12/23p40; 
BD). 
 
Bone marrow chimera. For the generation of bone marrow chimeras, donor mice were 
killed by CO2 inhalation. Femur, tibia, radius, and hipbones were removed and flushed 
with PBS to isolate bone marrow cells. Cells were then passed through a 70 μm pore size 
filter and washed with PBS. Recipient mice were lethally irradiated with 1,100 rads (split 
dose) and received 1 x 106 to 5 x 106 bone marrow cells. Engraftment took place over 6 
to 8 weeks before subjecting mice to orthotopic glioma rejection. 
 
Adoptive transfer. For adoptive transfer experiments, CD4+ T cells (L3T4) or CD8+ T 
cells (Ly-2) were MACS sorted with positive selection (Miltenyi Biotec). Subsequently, 
cells were injected i.v. in a 1:1 ratio of CD4+ and CD8+ T cells. 
 
Depletion of CD4+ T cells. On day -1, mice were injected i.p. with 500 μg anti-CD4 
(GK1.5; Bio X cell) or IgG2b (MCP-11; BioXCell) and then injected on day 0 with tumor 
cells as described below. Mice were injected every two weeks with the same amount of 
antibody. Depletion was confirmed by flow cytometry with an anti-CD4 antibody (RM4-
5; Biolegend) on a weekly basis.  
 
Orthotopic glioma inoculation. Inoculation into the right striatum was performed as 
previously described [120]. In brief, 7-12-week-old mice were i.p. injected with 
meloxicam (Metacam;1-2mg/kg body weight) before being anesthetized with 3.5 - 4% 
Isoflurane (Minrad) in an induction chamber. Mice were kept under anesthesia on the 
stereotactic frame (David Kopf Instruments) by delivering 3 % Isoflurane delivered 
through a nose adaptor. For tumor cell injections, a syringe (Hamilton; 75N, 26s/2”/2.5 
μl; blunt-ended) was positioned at the coordinates 1.5 mm lateral and 1 mm frontal of the 
bregma. The syringe was lowered by 4 mm and retracted 1 mm to form a small reservoir. 
A microinjection pump was used to inject 3-5 x 104 cells per 2 μl at a rate of 1μl/min 
(UMP-3; World precision Instruments Inc.). Two minutes after injection ended, the 
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needle was retracted at a rate of 1mm/min. Bone wax was used to close the site of injection 
(Aesculap; Braun), and the scalp wound was sealed with tissue glue (Indermil; Henkel). 
 
In vivo bioluminescent imaging. Tumor-bearing mice were injected with D-Luciferin 
(150mg/kg body weight; Caliper Life Science). Animals were transferred to a dark 
chamber of a Xenogen IVIS 100 (Caliper Life Sciences) imaging system, and 
luminescence was recorded. The Living Image 2.5 software (Caliper Life Sciences) was 
used to analyze the data. A circular region of interest (ROI; 1.46cm diameter) was defined 
around the tumor site, and photon flux was used to quantify tumor size. 
 
Survival analysis. Tumor-bearing animals were monitored by BLI, checked for 
neurological symptoms and weighed weekly until day 21 after glioma inoculation. 
Animals were checked daily from day 21 onwards. Upon showing symptoms such as 
apathy, severe hunchback posture, or weight loss exceeding 20 %, animals were 
euthanized by CO2 inhalation.  
 
Cell preparations. Cervical lymph nodes, spleen and the frontal part of the tumor-
bearing cerebral hemisphere were harvested, cut into small pieces and incubated in 
collagenase and DNAse (0.4 mg/ml). Subsequently, samples were passed through a 18G 
syringe. CNS cell suspensions were enriched by a 30% Percoll gradient (GE Healthcare; 
1.3 g/ml). Flow cytometric analysis was carried out as described below. 
 
Flow cytometry. The following antibodies were used for flow cytometry analyses: anti-
CD45 (30-F11; BioLegend), anti-CD45.1 (Ly-5.2; BioLegend), anti-CD45.2 (Ly-5.1; 
Biolegend), anti-CD11b (M1/70; BD), anti-CD4 (RM4-5; GK1.5; BioLegend), anti-CD8 
(53-6.7; BioLegend; BD), anti-CD44 (IM7; BioLegend), anti-CD62L (MEL-14; BD), 
anti-CD11c (N418; BioLegend), anti-Ly6C (AL-21; BD), anti-Ly6G (1A8; BioLegend); 
anti-Siglec-H (551; eBioscience), anti-CD24 (M1/69; BioLegend; BD), anti-MertK 
(DS5MMER; eBioscience), anti-CD64  (X54-5/7.1; Biolegend), anti-I-A/I-E-
AlexaFlour700 (M5/114.15.2; BioLegend), anti-CD103 (2E7; eBioscience), anti-CD86 
(GL-1; BioLegend), anti-Ki67 (SolA15; eBioscience), anti-CD3 (17A2; BD), anti-NK1.1 
(PK136; BioLegend), anti-CD19 (1D3; BD), anti-PDCA-1 (eBio129c; eBioscience) anti-
TCRVb5.1,5.2 (MR9-4; BioLegend). For the exclusion of dead cells, the Zombie Aqua 
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fixable viability kit or the Zombie NIR fixable viability kit (BioLegend) was used. Single 
cells were gated from the FSC-A/FSC-H gate. 
For tracking proliferation, MACS-sorted CD4+ and CD8+ T cells were CFSE-labeled 
according to the manufacturers` protocol (Thermo Fisher Scientific). Intracellular 
cytokine, transcription factor and Ki67 staining were performed using the eBioscience 
FoxP3 staining buffer set according to manufacturer’s instructions. The acquisition was 
performed on the FACS Canto II (BD), the LSRII Fortessa flow cytometer (BD) or the 
FACS Symphony (BD). Data analysis was performed using FlowJo Version 10 (Tree 
Star), proliferation indices calculated with FlowJo Version 9 (Tree Star). 
 
Statistical analysis. For all non-survival analyses of two experimental groups, an 
unpaired, two-tailed Student’s t-test was performed. For all non-survival analyses of three 
or more groups, a one-way ANOVA with Tukey`s multiple comparison test was 
performed. For statistical analysis of Kaplan-Meier survival curves, a Log-rank (Mantel-
Cox) test was used to calculate p-values. P-values <0.05 are considered statistically 
significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001). All quantitative analyses were 
performed with GraphPad Prism version 5.0a for Mac OSX (GraphPad Software, Inc). 
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9. Results 
9.1. Identifying the IL-12 responsive cell subsets required for 
tumor rejection 
9.1.1. Glioma rejection requires IL-12 receptor expression on 
hematopoietic cells 
To systematically investigate the role of brain-resident versus hematopoietic bone 
marrow (BM)-derived immune cells responsible for the tumor-suppressive effects of IL-
12, we generated BM chimeras by transferring BM from C57BL/6 WT into IL12rb2-/- 
mice or vice versa (Figure 7A). Upon challenge with GL-261luc:IL12Fc cells, we found 
that initial tumor growth was comparable among all groups until day 35 (Figure 7B, right 
panel). However, from day 35 onwards, mice that lacked IL12-responsive hematopoietic 
cells displayed accelerated tumor growth and were not able to reject IL-12 expressing 
glioma cells. In contrast, tumor control and survival were functionally restored in 
IL12rb2-/- mice receiving WT bone marrow cells (Figure 7B). 
 
 
Figure 7: Glioma rejection requires IL12-receptor expression on BM-derived cells. (A) Experimental 
setup for BM chimera using lethally irradiated CD45.1 WT, CD45.2 WT or IL12rb2-/- mice reconstituted 
with CD45.1 WT or IL12rb2-/- BM. (B) (Left) Survival of BM chimera challenged with GL-261luc:IL12Fc 
monitored for 90 days. (Right) Tumor development assessed with BLI (photon/s) emitted from the region 
of interest (ROI) around the tumor site (WT CD45.1 → WT CD45.2; n = 12), (IL12rb2-/- → WT CD45.1; 
n = 9), (WT CD45.1 → IL12rb2-/-; n = 12). Pooled data from two independent experiments. 
 
In summary, these results indicate that IL-12 tumor rejection relies on BM-derived cells 
responding to IL-12. 
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9.1.2. Tumor rejection requires IL-12-receptor signaling in CD8+ T cells 
Within the hematopoietic compartment, T cells and innate lymphoid cells represent 
potential candidate effector populations for IL-12-mediated tumor suppression [120, 166, 
183, 185, 187, 189]. Given that NK cells were not required for glioma rejection in our 
model [120], we investigated the involvement of CD4+ and CD8+ T cells in regards to IL-
12 receptor signaling.  
To understand whether CD4, CD8 or both T cell subsets are functionally required for IL-
12-mediated tumor rejection, we adoptively co-transferred MACS-purified CD4+ and 
CD8+ T cells into Rag1-/- mice using WT or IL12rb2-/- donors (Figure 8A). Once T cells 
expanded, all groups were challenged with IL12Fc tumors. As shown in Figure 8B, a 
complete responsive T cell compartment and functional IL-12 receptor signaling in CD8+ 
T cells was sufficient to permit IL-12-driven glioma suppression. 
 
 
Figure 8: Glioma rejection requires IL12-receptor signaling in CD8+ T cells. (A) Experimental setup 
for the adoptive transfer of T cells into Rag1-/- mice. Mice were challenged with IL-12 overexpressing GL-
261 tumor cells 17 days after adoptive T cell transfer. (B) (Left) Survival of mice monitored for 90 days. 
(Right) Tumor development quantified with BLI (photon/s) emitted from the ROI around the tumor site 
(Rag1-/- + WT CD4+ T cells + WT CD8+ T cells; n = 5), (Rag1-/- + IL12rb2-/- CD4+ T cells + WT CD8+ T 
cells; n = 2), (Rag1-/- + WT CD4+ T cells + IL12rb2-/- CD8+ T cells; n = 5), (Rag1-/- + IL12rb2-/- CD4+ T 
cells + IL12rb2-/- CD8+ T cells; n = 4). 
 
Next, we investigated T cell responses in an immune competent microenvironment. 
Therefore, mixed chimeric mice bearing both WT (CD45.1) and IL12rb2-/- or WT 
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(CD45.1) and WT (CD45.2) hematopoietic compartments were generated to study the 
competitive response between T cells deficient or functional in IL-12-signaling (Figure 
9A). Eight weeks after reconstitution, equal expansion of transferred cells was confirmed, 
and mice challenged with IL12Fc tumors (Figure 9B). 
 
 
Figure 9: Local IL-12 release induces proliferation of tumor-infiltrating CD8+, but not of CD4+ T 
cells. (A) Experimental setup for mixed bone marrow chimera. (B) (Left) Reconstituted mice from mixed 
BM chimera based on single positive CD45.1+ or CD45.2+ FACS staining in the blood and statistical 
summary (right). (C, D) Tumor-infiltrating CD8+ (C) and CD4+ T cells (D) on day 21 post i.c. challenge 
with GL-261luc:IL12Fc cells. (Left) Example FACS staining of Ki67+ T cells and CD45.1+ or CD45.2+ 
single positive cells. (Right) Statistical summary of the competitive response between the co-transferred 
populations (IL12rb2-/- + CD45.1 → CD45.1/2; n = 8), (CD45.2 + CD45.1 → CD45.1/2; n = 9). Pooled 
data from two independent experiments. 
 
The analysis of tumor-infiltrating lymphocytes (TILs) on day 21 post-injection showed 
an increased proliferation of the responsive CD8+ T cell fraction (Figure 9C) compared 
to CD8+ T cells derived from IL12rb2-/- donors, as assessed by Ki67+ staining. In contrast, 
the proliferative CD4+ T cell response was comparable among all groups (Figure 9D). 
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Given that IL-12 receptor signaling in CD4+ T cells was dispensable, we next aimed to 
understand the requirement of CD4+ T cells for IL-12-mediated tumor rejection. 
Therefore, mice were treated with an anti-CD4 depletion antibody (or the respective 
isotype control) before and during IL-12 tumor challenge (Figure 10A, B). As depicted 
in Figure 10C, mice lacking CD4+ T cells did not reject IL-12 expressing tumors. 
 
 
Figure 10: Glioma rejection requires CD4+ T cell-mediated activation of CD8+ T cells. (A) 
Experimental setup for the depletion of CD4+ T cells in WT mice before and during IL-12 tumor challenge. 
(B) Example staining from the blood one day before surgery of mice injected with an anti-CD4 depletion 
antibody or isotype control. (C) (Left) Survival of mice challenged with IL-12 overexpressing GL-261 
tumor cells monitored for 90 days (WT + isotype; n = 7), (WT + αCD4; n = 5). (Right) Example of BLI 
(photon/s) emitted from the ROI around the tumor site on day 7, 14 and 21 post-intracranial injection. 
 
In summary, these data suggest that glioma rejection mainly relies on the local action of 
IL-12 leading to the proliferation of tumor-infiltrating CD8+ T cells. CD4+ T cells are 
required for tumor rejection, but dispensable for IL-12 signaling. 
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9.2. IL-12 mediated glioma rejection in the context of the 
glioma-immune cycle 
9.2.1. Intratumoral versus LN-required immune response during 
glioma rejection 
Since IL-12 induced proliferation of T cells is limited to pre-activated T cells [167], we 
used the tumor model antigen chicken ovalbumin (cOva) expressed by GL-261 tumor 
cells (GL-261luc:cOva) to investigate the contribution of IL-12 on tumor-specific T cells 
during the priming and effector phase of glioma rejection. CFSE-labeled OT1 CD8+ and 
OT2 CD4+ T cells were adoptively transferred into mice challenged with an equal number 
of GL-261luc:cOva and GL-261luc:IL12Fc, GL-261luc:cOva and GL-261luc:Fc, GL-
261luc:Fc and GL-261luc:IL12Fc or with GL-261luc:Fc cells only (Figure 11A). 
By day five post adoptive transfer, the tumor size of the GL-261luc:cOva/IL12Fc and 
GL-261luc:Fc/IL12Fc the group was reduced compared to that of the GL-261luc:cOva/Fc 
and the control GL-261luc:Fc group, confirming the tumor-suppressive action of IL-12 
in this experimental setup (Figure 11B). We found OT1 (CD45.1/2) CD8+ T cells 
infiltrating the tumor proliferating in both the GL-261luc:cOva/IL12Fc and the GL-
261luc:cOva/Fc groups (Figure 11C). However, the transferred OT1 (CD45.1/2) CD8+ T 
cells from GL-261luc:cOva/IL12Fc tumors had a clear proliferative advantage as detected 
by the high peak of the CFSElow fraction and increased division index (Figure 11C, D). 
We could not detect any proliferation in GL-261luc:Fc/IL12Fc or GL-261luc:Fc tumors, 
confirming that the IL-12 induced proliferation of T cells is limited to pre-activated, 
tumor-specific T cells. Regarding the cervical lymph nodes, we only detected a low 
frequency of proliferating OT1 (CD45.1/2) CD8+ T cells in all groups (Figure 11E, F). 
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Figure 11: Local IL-12 induces proliferation of tumor-specific CD8+ T cells within the tumor, but not 
in the cervical lymph nodes. (A) Experimental setup for the adoptive transfer of CFSE-labelled OT1 
CD8+/OT2 CD4+ tumor-specific T cells into GL-261luc:cOva/IL12Fc, GL-261luc:cOva/Fc, GL-
261luc:FcIL12Fc or GL-261luc:Fc tumor bearing WT mice (B) BLI measurement on day 7, 16 and 21 after 
tumor cell inoculation (n ≥ 8/group)). (C, E) Tracking of tumor-specific OT1 CD8+ T cells based on the 
expression of CD45.1 in the tumor and cervical lymph nodes. (D, F) Statistical summary (%) of 
proliferating CD8+ T cells (CFSElow/int) and division index in the tumor and cervical lymph nodes. (Fc 
tumor; n = 5), (Fc/IL12Fc tumor; n = 2), (Fc/cOva tumor; n = 5), (IL12Fc/cOva; n =3). Representative 
experiment from two independent experiments. 
 
As depicted in Figure 12, we also analyzed the transferred, tumor-specific OT2 
(CD45.1/2) CD4+ T cells. Notably, we only detected a minor increase of proliferation of 
the transferred tumor-specific CD4+ T cells in GL-261luc:cOva/IL12Fc tumors compared 
to GL-261luc:cOva/Fc tumors (Figure 12A, B). Moreover, we could not detect any 
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proliferation of OT2 (CD45.1/2) CD4+ T cells in the cervical lymph nodes (Figure 12C, 
D). 
  
 
Figure 12: Local IL-12 does not increase the proliferation of tumor-specific CD4+ T cells in the tumor 
or cervical lymph nodes. (A, C) Tracking of tumor-specific OT2 CD4+ T cells based on the expression of 
CD45.1 in the tumor and cervical lymph nodes. (B) Statistical summary (%) of proliferating CD4+ T cells 
(CFSElow/int) and division index within the tumor. (D) Statistical summary (%) of proliferating CD4+ T cells 
(CFSElow/int) in the cervical lymph nodes. (Fc tumor; n = 5), (Fc/IL12Fc tumor; n = 2), (Fc/cOva tumor; n 
= 5), (IL12Fc/cOva; n =3). Representative experiment from two independent experiments. 
 
In summary, these data confirm that IL-12 mainly induces its effect locally by triggering 
proliferation of tumor-specific CD8+ T cells, while the small population of transferred 
CD4+ T cells detected at the tumor site displayed low to absent proliferation. Regarding 
the cervical lymph nodes, there was no increase of proliferation of tumor-specific CD4+ 
or CD8+ T cells in any of the analyzed groups. 
 
Since we could not detect changes in the proliferative status of tumor-specific T cell in 
the cervical lymph nodes, we decided to study the role of peripheral versus in situ priming 
during IL-12 mediated glioma rejection. Therefore, we treated mice with the sphingosine-
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derivative Fingolimod (FTY720). This immunomodulatory drug prevents lymphocyte 
egress by activating the S1P receptor 1, subsequently inducing down-regulation of the 
S1P receptor 1 and thereby retention of lymphocytes within secondary lymphoid organs 
[232]. 
To allow initial infiltration of immune cells to the tumor site, we let GL-261luc:IL12Fc 
and GL-261luc:Fc control tumors grow until day 11 before blocking lymphocyte egress 
(Figure 13A). As depicted in Figure 13B, FTY720 treatment led to a considerable 
reduction of T cells in the blood. Moreover, retention of lymphocytes within the 
secondary lymphoid organs abrogated IL-12 mediated tumor rejection (Figure 13C). 
  
Figure 13: Glioma rejection requires peripheral priming of T cells. (A) Experimental setup for blocking 
lymphocyte egress from secondary lymphoid organs with FTY720. (B) Example staining for CD4+ and 
CD8+ T cells in the blood from mice injected i.p. with FTY720 or PBS. (C) (Left) Survival of mice i.c. 
challenged with GL-261luc:Fc or GL-261luc:IL12Fc monitored for 90 days (PBS + GL-261luc:Fc; n = 6), 
(FTY720 + GL-261luc:Fc; n = 8), (PBS + GL-261luc:IL12Fc; n = 5), (FTY720 + GL-261luc:IL12Fc; n = 
3). (Right) Example of BLI (photon/s) emitted from the ROI around the tumor site. 
 
We therefore concluded that also in the context of IL-12 mediated glioma rejection, 
priming of tumor-specific T cells involves secondary lymphoid organs. 
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9.2.2. Tumor-derived IL-12 induces a change in the myeloid infiltration 
pattern 
Given the observation of IL-12 mainly exerting its effects locally, we addressed the 
question of how tumor-derived IL-12 affects APCs in the tumor microenvironment 
potentially shaping the anti-tumor immune response.  
IL-12 led to a substantial increase of all hematopoietic-derived CD45hi CD11bneg/int/hi cells 
in the tumor microenvironment (Figure 14A), while the CD45int CD11b+ resident 
microglia population was not affected (Figure 14A, B). We found that absolute numbers 
of macrophages (CD64+ MertK+) and moDCs (CD11c+ Ly6Clow/hi MHCIIhi CD11b+) were 
elevated in the presence of IL-12, whereas the frequency of inflammatory monocytes 
(Ly6C+ MHCII-) was significantly decreased (Figure 14C-E).  
These observations prompted us to study IL-12-mediated glioma suppression in ccr2-/- 
mice. Mice deficient in CCR2 signaling display defective monocyte/macrophage 
recruitment during immune responses [233] and virtually lack infiltration of CD45hi 
CD11bhi cells upon glioma induction (Figure 14F). However, the challenge of these mice 
with GL-261luc:IL12Fc tumor cells conferred a survival advantage equally to WT mice 
challenged with GL-261luc:IL12Fc tumors (Figure 14G), indicating that CCR2-
dependent recruitment of myeloid cells to the tumor site is not required for IL-12-
mediated glioma rejection. 
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Figure 14: Local IL-12 release indirectly increases the recruitment CCR2-dependent myeloid cells. 
(A) Gating strategy of tumor-infiltrating myeloid cells on day 21 post injection of WT mice bearing GL-
261luc:IL12Fc or GL-261luc:Fc tumors pre-gated on non-neutrophils. Macrophages, inflammatory 
monocytes and moDCs were gated from CD45+ CD11b+ cells, identifying CD64+MertK+ macrophages and 
inflammatory monocytes and moDCs within the MertKneg population. Monocytes and moDCs were 
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distinguished based on MHCII expression (B-E) Statistical summary of percentages and absolute numbers 
(normalized to mg tissue) of CD45int CD11b+ microglia, CD64+ MertK+ macrophages, Ly6C+ MHCII- 
inflammatory monocytes and MHCII+ CD11b+ CD11c+ MertK- monocyte-derived DCs (WT + GL-
261luc:Fc; n = 6), (WT + GL-261luc:Fc; n = 5). (F) Flow cytometric analysis of infiltrating CD45hi CD11bhi 
cells in WT and ccr2-/- mice challenged with intracranial GL-261luc:IL12Fc or GL-261luc:Fc tumors. (G) 
(Left) Survival of WT or ccr2-/- mice challenged with GL-261luc:IL12Fc or GL-261luc:Fc cells monitored 
over 90 days. (Right) BLI emitted from the ROI around the tumor site measured on a weekly basis (WT + 
GL-261luc:Fc; n = 8), (WT + GL-261luc:IL12Fc; n = 9), (ccr2-/- + GL-261luc:Fc; n = 10), (ccr2-/- + GL-
261luc:IL12Fc; n = 8). Pooled data from two independent experiments. 
______________________________________________________________________ 
 
Since CCR2-dependent cells were dispensable for tumor rejection, we focused our 
analysis on other, CD11b- tumor-infiltrating APCs and found that CD24+CD103+ 
migratory DCs were significantly increased in the presence of IL-12 (Figure 15A). We 
thus decided to study IL-12 tumor rejection in Basic leucine zipper transcription factor 
ATF-like (Batf)3-/- mice. C57BL/6 mice deficient in the transcription factor Batf3 have 
previously been shown to lack CD8a+ DCs only in the spleen while entirely lacking the 
CD103+ migratory DC compartment [234]. Moreover, this population has been shown to 
be supportive for anti-tumor immune responses in distinct preclinical melanoma models 
[235-238]. 
As depicted in Figure 15C, Batf3-/- lack CD103+ DCs in the tumor microenvironment, 
even in the presence of IL-12. The challenge of these mice with GL-261luc:IL12Fc tumor 
cells conferred a survival advantage equally to WT mice challenged with GL-
261luc:IL12Fc (Figure 15D). However, following the overall tumor development, mice 
lacking CD103+ DCs had a delay in rejecting IL-12 overexpressing tumors (Figure 15D).  
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Figure 15: The role of Batf3 during IL-12 mediated tumor rejection. (A) Gating strategy for CD103+ 
CD24+ CD11c+ DCs in the tumor microenvironment pre-gated from CD45+ CD11b- cells. (B) Statistical 
summary of percentages and absolute numbers (normalized to mg tissue) of CD103+ CD24+ CD11c+ DCs 
(WT + GL-261luc:Fc; n = 6), (WT + GL-261luc:Fc; n = 5). (C) Representative flow cytometric analysis of 
infiltrating CD45hiCD11bhi cells and CD103+ CD24+ DCs in WT and Batf3-/- mice challenged with 
intracranial GL-261luc:IL12Fc or GL-261luc:Fc tumors. (D) (Upper) Survival of WT or Batf3-/- mice 
challenged with GL-261luc:IL12Fc or GL-261luc:Fc cells monitored over 90 days. (Lower) BLI emitted 
from the ROI around the tumor site measured on a weekly basis (WT + GL-261luc:Fc; n = 4), (WT + GL-
261luc:IL12Fc; n = 7), (Batf3-/- + GL-261luc:Fc; n = 7), (Batf3-/- + GL-261luc:IL12Fc; n = 6). 
 
In summary, these results show that lack of myeloid cells due to lack of CCR2 or Batf3 
does not impact survival, but lack of Batf3 alters the kinetic of the effector phase. 
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10. Discussion 
Glioblastoma - the most malignant type of brain cancer - is associated with poor prognosis 
having a 5-year survival rate of 33.6%, despite therapy consisting of maximal surgery, 
radiotherapy, and chemotherapy [88]. Notably, glioblastoma ultimately relapses in almost 
all patients, with no treatment option currently available prolonging survival upon relapse 
[84]. Given the success of immunotherapy with immune checkpoint inhibitors for the 
treatment of other tumor types, such as the FDA approved checkpoint inhibitors targeting 
the molecules PD-1 and CTLA-4, immunotherapy has become an appealing treatment 
strategy for glioblastoma [84, 110-115]. Thus, reverting the suppressive tumor 
microenvironment into a pro-inflammatory microenvironment to favor tumor control has 
been a subject of research in multiple preclinical glioma models. Studies primarily 
focused on strengthening T cell activation either by activating co-stimulatory receptors 
(e.g., OX-40) or blocking of co-inhibitory receptors (e.g., PD-1 and CTLA-4) combined 
with radiotherapy or by combining blockade of co-inhibitory receptors with intratumoral 
cytokine delivery, such as IL-12. Notably, these approaches have been shown to induce 
anti-tumor responses leading to prolonged survival in distinct preclinical glioma models 
[84, 105, 116, 117, 120, 207]. In this respect, we have previously shown that reverting 
the suppressive tumor microenvironment into a pro-inflammatory microenvironment is 
achievable, by combining intratumoral IL-12 with systemic blockade of the co-inhibitory 
receptor CTLA-4 on T cells. Moreover, we could show that GL-261 glioma rejection 
required T cells and was perforin-dependent [120]. 
 
While the tumor suppressive capacity of IL-12 has long been known [166, 183, 187, 189], 
early clinical trials administering IL-12 not only led to low response rates but also to the 
occurrence of severe adverse side effects resulting in fatalities [166, 223, 239, 240]. 
Aiming to minimize toxicity while maximizing efficacy, current clinical trials use local 
administration of IL-12 [209, 216]. In this respect, there has been an increase in registered 
studies since 2011 on clinicaltrials.gov [208]. However, in addition to targeted delivery 
to the tumor site, translation into the human situation also requires an immunological 
understanding of the underlying mechanistics and cell types involved.  
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10.1. Investigating the IL-12 responsive cell subset 
Given the vast amount of studies performed with IL-12 in preclinical models, it has 
become increasingly clear that IL-12 not only acts tissue-specific but also in a time and 
dose-dependent fashion. This is best exemplified in studies available in the B16 
melanoma model, where overexpression of IL-12 leads to tumor suppression mediated by 
Rorγt-dependent ILCs [185, 186]. In contrast, treatment of established B16 tumors was 
shown to require adaptive immunity mediated by CD8+ T cells [185-187]. Moreover, 
when the dose of systemically administered IL-12 was increased, treatment of established 
B16 tumors involved NK and NKT cell-dependent mechanisms of tumor suppression 
[183, 188]. To add another level of complexity, established B16 melanoma tumors treated 
with adoptively transferred CD8+ T cells expressing functional single-chain IL-12 
induced a programmatic change in tumor-infiltrating myeloid cells including 
macrophages, DCs, and MDSCs sensing IL-12. In this experimental setup, myeloid cells 
sensing IL-12 were crucial for the induction of CD8+ T cell-mediated tumor suppression 
[241]. In this respect, other studies reported IL-12 receptor expression on cells of myeloid 
cells origin and tonsillar B cells in addition to the established cell types expressing the 
IL-12 receptor including ILCs, NKT, and T cells [175, 176]. Moreover, IL-12 receptor 
expression was found in non-hematopoietic cells, such as keratinocytes involved in 
mediating a tissue-protective response in the Aldara-induced psoriatic plaque formation 
model [180]. Regarding preclinical glioma models, studies have suggested both T cells 
and NK cells to be involved in IL-12 mediated glioma rejection [199-202, 205-207]. 
Notably, these studies differ in treatment initiation and routes of delivery of intratumoral 
IL-12. Moreover, the requirement of IL-12 receptor expression on the involved cell types 
for tumor rejection was not assessed in these studies [120, 203, 207]. 
 
Our systematic analyses of the responding cell types required for IL-12 mediated glioma 
rejection showed that IL-12 tumor rejection relies on BM-derived cells responding to IL-
12 (Figure 7). Thus, these findings excluded the involvement of CNS-resident cells, 
previously reported to mediate recovery in an experimental model of VSV infection of 
the CNS [177]. Moreover, the requirement of IL-12 receptor-expressing microglia was 
also discarded, despite the reported upregulation of this receptor in these cells in primary 
culture conditions upon stimulation with IL-12 [178, 179]. 
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Within the hematopoietic compartment, ILCs, NKT, and T cells represent typical 
candidate effector populations expressing the IL-12 receptor [120, 166, 183, 185, 187, 
189]. However, we previously established that ILCs including NK cells were not required 
for glioma rejection in our model [120]. Thus, we investigated the involvement of CD4+ 
and CD8+ T cells regarding IL-12 receptor signaling. While IL-12 receptor signaling in 
CD4+ T cells was dispensable, we found that depletion of the CD4+ T cell compartment 
abrogated rejection (Figure 8 and Figure 10). These findings agree with a recent 
publication of a glioblastoma stem-like cell model (GSC005) treated with a combination 
of oncolytic virus releasing IL-12 (G47Δ-mIL12) applied together with the blockade of 
the inhibitory molecules CTLA-4 and PD-1, in which depletion of CD4+ T cells abrogated 
the efficacy of treatment [207]. In this regard, CD4+ T cells serve multiple purposes, such 
as providing help for CD8+ T cells and B cells [242]. B cells, require CD4+ T cells for 
germinal center formation, class switching and affinity maturation. In our experimental 
setups, IL-12 release by tumor cells induced an influx of B cells (data not shown), 
however, transfer of merely T cells into Rag1-/- mice led to tumor rejection in the absence 
of B cells. Thus, this rules out the requirement of B cells during IL-12-mediated glioma 
rejection [175, 243].  
Within strong inflammatory settings, CD8+ T cells do not require the support of CD4+ T 
cells for activation. However, the absence of CD4+ T cells leads to poorly responding 
memory cells during reactivation [242]. In this regard, we found that functional IL-12 
receptor signaling in CD8+ T cells was essential to induce IL-12-driven glioma 
suppression (Figure 8). The finding of CD8+ T cells required for tumor rejection coincides 
with our previously published findings showing perforin-dependency during IL-12 
mediated tumor rejection [120] and the IL-12-induced enhanced transcription of cytotoxic 
granule-associated molecules such as perforin and granzyme B [167, 244]. Moreover, 
tumor-derived IL-12 mainly exerted its effects locally by increasing proliferation of 
tumor-infiltrating CD8+ T cells (Figure 9). This was shown in an immune competent 
microenvironment using mixed chimeric mice bearing WT (CD45.1) and IL12rb2-/- or 
WT (CD45.1) and WT (CD45.2) hematopoietic compartments. Also using this 
experimental setup, no changes were observed in the myeloid compartment (data not 
shown), ruling out the contribution of these cells sensing IL-12 as described by Kerkar et 
al. in the treatment of B16 melanoma. [241].  
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Concluding, our results support the mechanism of IL-12-driven glioma rejection to be 
mainly dependent on the sensing of IL-12 locally by the effector cells, which are then 
enabled via a stronger “signal 3” to kill proliferating tumor cells more efficiently. 
 
10.2. IL-12 mediated glioma rejection in the context of the 
glioma-immune cycle 
In addition to elucidating the IL-12 responsive cell type required for inducing tumor 
rejection, we investigated the contribution of IL-12 in generating the anti-tumor immune 
response within the cancer immune cycle. This multistep process – consisting of antigen 
release, presentation, priming/activation of T cells in tumor draining lymph nodes, 
trafficking and infiltration of T cells into tumors, recognition, and killing of cancer cells 
– has previously been described for malignant tumors of the CNS. In this regard, APCs 
transporting CNS antigens are known to be drained by the cerebrospinal fluid into cervical 
lymph nodes [85]. Cervical lymph nodes have been established as the location of priming, 
leading to clonal expansion, acquisition of effector functions and specific adhesion 
molecule patterns of tumor-specific T cells [245, 246]. To assess the contribution of IL-
12 in priming and shaping the effector response within the glioma immune cycle, we used 
a tumor model expressing the ovalbumin antigen to enable the tracking of adoptively 
transferred tumor-specific OT1 CD8+ T cells and OT2 CD4+ T cells (Figure 11 and Figure 
12). We found that IL-12 induced CD8 T cell proliferation within the tumor 
microenvironment, which was limited to pre-activated T cells. This observation coincides 
with our previous finding showing IL-12 inducing local proliferation of IL-12 receptor 
expressing polyclonal CD8+ T cells. In contrast, we only detected minor ovalbumin-
specific CD8 T cell proliferation in the cervical lymph nodes, an observation likely due 
to low antigen availability caused by injecting mixtures of tumor cells. Additionally, these 
observations suggest that the transferred tumor-specific CD8+ T cells in the cervical 
lymph nodes swiftly egress from the lymph node to the circulation upon activation and 
subsequently to the tumor site. In this respect, it has previously been published that the 
final functional maturation of tumor-specific CD8+ T cells in the GL-261 glioma model 
occurs within the tumor microenvironment [246].  
As for the CD4+ T cell compartment, no proliferation was observed, neither in the tumor 
microenvironment nor the cervical lymph nodes. This suggests that the endogenous 
tumor-specific CD4+ T cell response is sufficient to sustain tumor-specific CD8+ T cell 
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immunity and that the availability of MHC class II OVA peptide might be limited in this 
experimental setup.  
Notably, the GL-261 tumor cell line also expresses a wide range of known tumor antigens 
such as the glycoprotein 100 (gp100) and tyrosine-related protein-2 (Trp-2) [149, 153], 
increasing its immunogenicity and supporting T cell responses even in the absence of 
artificially introduced antigens such as ovalbumin. While in mice, many cancer 
immunotherapeutics showed robust efficacy, similar results have been difficult to achieve 
in humans. This discrepancy might be due to the neo-epitope load in murine cell lines 
which might not reflect the human situation that usually shows a variable but rather low 
amount of mutations. Even though human glioblastoma carries an intermediate 
mutational load compared to other tumor types [247, 248], the necessity of improving 
antigen presentation in glioblastoma treatment is exemplified by multiple strategies 
currently being exploited. Among those approaches are loading of glioblastoma-
associated antigens/glioblastoma specific antigens and manipulation of co-stimulatory 
and co-inhibitory signals of DCs to boost anti-tumor immunity [249]. 
Nevertheless, not observing any proliferation of ovalbumin-specific T cells in the cervical 
lymph nodes prompted us to study the role of peripheral versus in situ priming during IL-
12 mediated glioma rejection. The blockade of lymphocytes within secondary lymphoid 
organs by Fingolimod showed that IL-12 mediated glioma rejection does require 
peripheral priming (Figure 13). These results are in line with our previous findings of 
CCR7 and lymphotoxin-beta receptor (Ltbr) dependency during IL-12 glioma challenge 
(data not shown). Given that IL-12 mediated tumor rejection required peripheral priming, 
even though we could not detect proliferating tumor-specific T cells in the cervical lymph 
nodes, we focused on the interaction of myeloid cells and T cells within the tumor 
microenvironment.  
 
Our thorough characterization of the tumor microenvironment revealed that tumor-
derived IL-12 led to a substantial infiltration of all myeloid cells into the tumor 
microenvironment (Figure 14). Coinciding with previous reports, we found that moDCs 
displayed the main fraction of infiltrating myeloid cells in the context of local IL-12 
release in the GL-261 tumor model [250]. Despite the functional role that moDCs have 
been given in establishing robust T cell responses leading to tumor clearance, we found 
that moDCs and macrophages were dispensable for IL-12 mediated tumor rejection in our 
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model. These results contradict a recently published study showing a key role of F4/80+ 
macrophages in glioblastoma rejection upon CTLA-4, PD-1 and IL-12 treatment [207]. 
The differences in the glioblastoma models used and the combination with checkpoint 
blockade could, however, explain a differential requirement of cell types for tumor 
rejection.  
We could not observe an increase of microglia in the presence of IL-12 compared to 
control tumors. Even though microglia cells can cross-present tumor antigens both in vitro 
and in vivo [251, 252], they are known to inefficiently present glioma antigens to 
cytotoxic CD8+ T cells [253]. Also, they have been shown to support immunosuppression 
through the release of cytokines such as TGF-β and IL-10 and by losing MHC expression 
[77, 254]. To fully understand the contribution of microglia during IL-12 mediated glioma 
rejection would require the generation of BM chimeras using MHCI-/- and MHCII-/- into 
WT (and vice versa). Alternatively, co-culture assays using sorted microglia from 
ovalbumin-expressing tumors and infiltrating DCs cultured with tumor-specific OT1 
CD8+ or OT2 CD4+ T cells would need to be performed. However, the low number of 
DC infiltrates, and microglia found in GL-261 tumors provide a significant hurdle to 
perform assays of such kind. 
By looking beyond CCR2-dependent cells and the response of resident microglia, we 
found that IL-12 increased the expansion of a small subset of CD103+ DCs. This 
population has previously been shown to be supportive for anti-tumor immune responses 
in distinct melanoma models [235-238]. The development of CD103+ DCs is dependent 
on the transcription factors interferon regulatory factor 8 (IRF8), zinc finger and BTB 
domain containing 46 (Zbtb46) and Batf3. Moreover, CD103+ DCs are generated upon 
stimulation with GM-CSF and Fms-like tyrosine kinase-3 ligand (Flt3L). Notably, 
CD103+ DCs have been found to be increased in regressing tumors in both humans and 
mice [235]. Migrating in a CCR7-dependent fashion, this type of DC has been shown to 
support T cell-mediated tumor suppression and to be required for expansion and 
activation at the tumor site enhancing the response to combined PD-L1 and BRAF 
inhibition [236, 237]. Moreover, Spranger et al. showed that effector T cell trafficking 
and adoptive T cell therapy rely on CD103+ DCs found in inflamed tumors [238]. Our 
data shows that Batf3-/- mice lacking CD103+ migratory DCs succumbed to glioma 
slightly earlier compared to WT controls in the absence of IL-12, suggesting a supportive 
role of Batf3-dependent DCs for the activation of T cells. However, IL-12 conferred 
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survival in Batf3-/- mice as it did with the WT counterparts (Figure 15). Notably, tumor 
growth is slightly different with WT mice being able to reject, while Batf3-/- mice seem 
to control the tumors, but are not able to reject IL-12 expressing tumors. These results 
suggest that CD103+ DCs support the effector phase of T cell-mediated tumor killing, but 
also that other cellular players are involved in T cell priming and can partially compensate 
for the lack of migratory DCs. One hypothesis to the fact that mice still survive in the 
absence of CD103+ DCs could be due to the capacity of GL-261 tumor cells to upregulate 
MHC expression in response to IFN-γ [149]. Even though we previously established that 
IL-12 mediated glioma rejection is independent of IFN-γ, it is conceivable that IFN-γ 
contributes to the compensatory mechanism leading to tumor cell killing. In this respect, 
it would be interesting to determine the extent of MHC upregulation by flow cytometry 
on ex vivo tumor cells in the context of IL-12. 
 
10.3. Concluding remarks and future directions 
Using a preclinical glioma model, we elucidated the mechanism of IL-12 mediated tumor 
rejection. Mainly exerting its effects on tumor-infiltrating cytotoxic CD8+ T cells, we 
found that IL-12 induces an infiltration of myeloid cells into the tumor microenvironment, 
amongst which migratory DCs supported the effector phase of rejection. Since mice 
lacking migratory DCs tolerated, albeit struggled to reject, their tumors, we propose that 
the direct interaction of tumor cells with cytotoxic CD8+ T cells is critical for the killing 
of tumor cells. In this respect, from a translational perspective, it would be interesting to 
investigate ways to modulate influx and function of CD103+ DCs into tumors. Given the 
intermediate mutational burden in glioblastoma, it would be interesting to exploit distinct 
strategies aiming to enhance DC efficacy as an additional treatment angle, improving the 
immune response even in less immunogenic settings than the GL-261 tumor model. While 
early treatment with Flt3L, driving DC development, led to inhibition of glioma 
progression [255-257], it would be interesting to determine whether late-stage therapy 
with Flt3L in combination with IL-12 or anti-CTLA-4 blockade can confer survival. 
Given that no good predictive biomarker is currently available to assess treatment 
efficacy, it would also be interesting to investigate CD103+ DCs as a potential biomarker 
for the response pre/post therapy of responders vs. non-responders. 
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Concluding, our findings provide new insights into the mechanism of IL-12 mediated 
glioma rejection. These include the requirement of directly and indirectly responsive cell 
types to consider as targets to boost anti-tumor immunity. 
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14. Appendix 
Disclaimer 
The appendix is based on the following manuscript: 
 
“Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–
mediated glioma rejection.” 
Johannes vom Berg, Melissa Vrohlings, Sergio Haller, Aladin Haimovici, Paulina Kulig, 
Anna Sledzinska, Michael Weller, and Burkhard Becher. 
J Exp Med. 2013 Dec 16;210(13):2803-11. 
 
Contribution:  M.V. contributed the data on the CTLA-4 expression on TILs (Figure 2F) 
comparing Fc and IL-12Fc tumors. Moreover, M.V. performed the 
experiment of perforin-1 gene expression by NK, CD4+ and CD8+ T cells 
infiltrating the tumor (Figure 4E). 
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